Exhibitors at UBIFRANCE French Pavilion
Exhibitors at UBIFRANCE French Pavilion
Exhibitors at UBIFRANCE French Pavilion
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
BIO'2011<br />
Bio inteRn<strong>at</strong>ionaL ConVention<br />
june 27 – 30, 2011<br />
Washington DC<br />
Welcome to the <strong>French</strong> <strong>Pavilion</strong>
<strong>UBIFRANCE</strong> and the network of Trade Commissions<br />
together constitute the <strong>French</strong> government’s corpor<strong>at</strong>e<br />
intern<strong>at</strong>ional expansion support framework, and,<br />
every year, help over 13,000 companies of all sizes and<br />
from all sectors to develop their activities worldwide,<br />
thanks to the expertise of 2,500 staff based in France<br />
and in 120 countries, who oper<strong>at</strong>e through the Trade<br />
Commissions of the <strong>French</strong> Embassies, a network of<br />
press offices and numerous approved partners.<br />
<strong>UBIFRANCE</strong> and the network of Trade Commissions<br />
offer <strong>French</strong> businesses a complete range of products<br />
and support services for their expansion into foreign<br />
markets – targeted inform<strong>at</strong>ion about opportunities<br />
and major players in every sector; upd<strong>at</strong>es on changes<br />
in laws and regul<strong>at</strong>ions; d<strong>at</strong>a on intern<strong>at</strong>ional funding<br />
and invit<strong>at</strong>ions to tender; sector monitoring services;<br />
invit<strong>at</strong>ions to canvassing missions, trade fairs abroad,<br />
and partnership meetings; help with intern<strong>at</strong>ional press<br />
coverage, etc. The Agency also runs the Intern<strong>at</strong>ional<br />
Voluntary Service in Business employment scheme (VIE)<br />
for companies seeking intern<strong>at</strong>ionally mobile gradu<strong>at</strong>es.<br />
Invest in France Agency (IFA) promotes and facilit<strong>at</strong>es<br />
intern<strong>at</strong>ional investment in France. The IFA network<br />
oper<strong>at</strong>es worldwide. IFA works in partnership with<br />
regional development agencies to offer intern<strong>at</strong>ional<br />
investors business opportunities and customized<br />
services all over France. For more inform<strong>at</strong>ion, please<br />
visit www.investinfrance.org<br />
Invest in France (IFA)<br />
77 boulevard saint jacques<br />
75680 Paris Cedex 14 – France<br />
Phone : +33 1 44 87 17 17 / +33 1 40 74 73 19<br />
Fax : +33 1 40 74 73 27<br />
email : info@investinfrance.org<br />
Web site : investinfrance.org
PARTICIPANTS<br />
Partners<br />
ACCINOV ...........................................................................................6<br />
ALSACE BIOVALLEY ......................................................................6<br />
ALSACE INTERNATIONAL ................................................................7<br />
ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS ..............................7<br />
ATLANPOLE BIOTHERAPIES ........................................................8<br />
AUVERGNE BIOCLUSTER .................................................................8<br />
BIOCITECH ........................................................................................9<br />
BIOPÔLE CLERMONT-LIMAGNE ......................................................9<br />
BRETAGNE INTERNATIONAL .........................................................10<br />
CANCER BIO SANTÉ ...................................................................10<br />
CANCER CAMPUS ® .........................................................................11<br />
CANCÉROPÔLE CLARA ..................................................................11<br />
CAPBIOTEK .....................................................................................12<br />
COMMUNAUTÉ URBAINE DU GRAND TOULOUSE.........................12<br />
CRITT SANTÉ BRETAGNE ...............................................................13<br />
ESSONNE CHAMBER OF COMMERCE & INDUSTRY .....................13<br />
ESSONNE SOUTH PARIS REGION ..................................................14<br />
EUROBIOMED .............................................................................14<br />
GENOPOLE ......................................................................................15<br />
LILLE EURASANTÉ .........................................................................15<br />
LYON CHAMBER OF COMMERCE & INDUSTRY .............................16<br />
LYONBIOPOLE ............................................................................16<br />
MEDICEN PARIS REGION ...........................................................17<br />
MONTPELLIER AGGLOMÉRATION ..................................................17<br />
ONLYLYON - ADERLY ......................................................................18<br />
ONLYLYON - GREATER LYON ..........................................................18<br />
PARIS CHAMBER OF COMMERCE AND INDUSTRY .......................19<br />
PARIS REGION ECONOMIC DEVELOPMENT AGENCY ....................19<br />
PROLOGUE BIOTECH - SICOVAL ....................................................20<br />
PROVENCE PROMOTION ................................................................20<br />
TEAM CÔTE D’AZUR ........................................................................21<br />
TECHNOPOLE CBS .........................................................................21<br />
UNIVERSITÉ DE LYON - LYON SCIENCE TRANSFERT ...................22<br />
<strong>French</strong> Competitiveness Cluster<br />
ComPanies<br />
ADOCIA ............................................................................................24<br />
AEPODIA..........................................................................................24<br />
AFFILOGIC .......................................................................................25<br />
ALAXIA .............................................................................................25<br />
ALIZE PHARMA ...............................................................................26<br />
ALMETIS ..........................................................................................26<br />
ALZ PROTECT..................................................................................27<br />
AMATSI ............................................................................................27<br />
ANALGESIA PARTENERSHIP ..........................................................28<br />
ANIMASCOPE ..................................................................................28<br />
ANS BIOTECH - AUVERGNE NEUROSCIENCES .............................29<br />
ARIANA PHARMACEUTICALS .........................................................29<br />
ATLANTIC BONE SCREEN ..............................................................30<br />
AVOGADRO ......................................................................................30<br />
BIOFILM CONTROL .........................................................................31<br />
BIO-MODELING SYSTEMS ..............................................................31<br />
BIOSIMS TECHNOLOGIES ...............................................................32<br />
BIOTRIAL .........................................................................................32<br />
CABINET REGIMBEAU ....................................................................33<br />
CELLECTIS BIORESEARCH ............................................................33<br />
CHELATEC .......................................................................................34<br />
CILOA...............................................................................................34<br />
CLICDATA ........................................................................................35<br />
COLCOM ..........................................................................................35<br />
DBV TECHNOLOGIES ......................................................................36
PARTICIPANTS<br />
DOMAIN THERAPEUTICS ...............................................................36<br />
ERYTECH PHARMA .........................................................................37<br />
EUROFINS OPTIMED ......................................................................37<br />
EVEON .............................................................................................38<br />
FLAMEL TECHNOLOGIES ...............................................................38<br />
GELARC ...........................................................................................39<br />
GENOWAY ........................................................................................39<br />
GENTICEL .......................................................................................40<br />
HARMONIC PHARMA ......................................................................40<br />
HELIOSBIOSCIENCES .....................................................................41<br />
HEMARINA ......................................................................................41<br />
HTL BIOTECHNOLOGY ....................................................................42<br />
ICDD ................................................................................................42<br />
IMABIOTECH ...................................................................................43<br />
IMMUNID TECHNOLOGIES .............................................................43<br />
INCELL ART ....................................................................................44<br />
INDICIA BIOTECHNOLOGY ..............................................................44<br />
INGEN BIOSCIENCES .....................................................................45<br />
INNOBIOCHIPS ...............................................................................45<br />
INSTITUT MERIEUX.........................................................................46<br />
IRIS PHARMA ..................................................................................46<br />
KAYENTIS ........................................................................................47<br />
LABORATOIRE ICARE......................................................................47<br />
LFB ..................................................................................................48<br />
MAGNISENSE ..................................................................................48<br />
MEDINCELL ....................................................................................49<br />
MEDIT ..............................................................................................49<br />
METABRAIN RESEARCH .................................................................50<br />
MILLEGEN .......................................................................................50<br />
NETRIS PHARMA ............................................................................51<br />
NEUROFIT .......................................................................................51<br />
NICOX ..............................................................................................52<br />
NOKAD ............................................................................................52<br />
NOSOPHARM ..................................................................................53<br />
NOVALIX ..........................................................................................53<br />
ONCODESIGN ..................................................................................54<br />
ONCOMEDICS .................................................................................54<br />
ONLY FOR CHILDREN PHARMACEUTICALS ..................................55<br />
OROXCELL.......................................................................................55<br />
OXELTIS ...........................................................................................56<br />
PHARMAXON...................................................................................56<br />
PHENOPRO .....................................................................................57<br />
POLYPLUS-TRANSFECTION ...........................................................57<br />
PORSOLT .........................................................................................58<br />
POXEL .............................................................................................58<br />
PRESTWICK CHEMICAL..................................................................59<br />
PROVEPHARM.................................................................................59<br />
PX’THERAPEUTICS .........................................................................60<br />
QUINTEN .........................................................................................60<br />
RHENOVIA PHARMA .......................................................................61<br />
ROOWIN ..........................................................................................61<br />
SYNTHELIS ......................................................................................62<br />
TB DRUG BOOST .............................................................................62<br />
TEXCELL .........................................................................................63<br />
TFCHEM ..........................................................................................63<br />
THERALPHA ....................................................................................64<br />
TRANSGENE ...................................................................................64<br />
TROPHOS ........................................................................................65<br />
VALYSCO ..........................................................................................65<br />
VIVALIS ............................................................................................66<br />
X’PROCHEM ....................................................................................66<br />
ZOPHIS ............................................................................................67
PARTNERS
ACCINOV<br />
321 avenue Jean Jaurès<br />
69007 LYON - FRANCE<br />
Phone: +33 6 20 72 17 67<br />
Fax: +33 4 72 70 48 29<br />
Email: bernard.mandrand@lyonbiopole.com<br />
Web site: www.accinov.com<br />
Contact: Bernard MANDRAND<br />
acCInov is an innov<strong>at</strong>ion pl<strong>at</strong>form of 6000 sq.m. in Lyon Gerland, part of Lyonbiopole’s<br />
infrastructure policy to support innov<strong>at</strong>ion. This project follows Lyonbiopôle’s Infectious<br />
Diseases Centre, open in April 2009 on the Charles Merieux campus in Lyon Gerland.<br />
The new pl<strong>at</strong>form intends to host pl<strong>at</strong>forms in pre-clinical and clinical research in<br />
biotechnology and biopharmaceuticals. This new facility will be dedic<strong>at</strong>ed to start-ups<br />
and SMBs, new or emerging, to provide services in the areas of biological analysis and<br />
biomanufacturing for the development of new health products for prevention, therapy<br />
or diagnostic. acCInov is looking for potential SMBs willing to set up their activity in<br />
Europe.<br />
ALSACE BIOVALLEY<br />
Parc d’Innov<strong>at</strong>ion<br />
9 boulevard Gonthier d’Andernach<br />
67400 ILLKIRCH - FRANCE<br />
Phone: +33 3 90 40 30 00<br />
Fax: +33 3 90 40 30 01<br />
Email: admin@alsace-biovalley.com<br />
Web site: www.alsace-biovalley.com<br />
Alsace BioValley is your ideal partner for an easy access to: Licensing opportunities;<br />
R&D collabor<strong>at</strong>ions and projects funding; Innov<strong>at</strong>ive technological pl<strong>at</strong>forms;<br />
Competitive CRO and CMO; Establishment of European subsidiaries. BioValley is also<br />
a leading trin<strong>at</strong>ional biocluster in Europe spreading over Alsace-France, South Baden-<br />
Germany, and Basel area-Switzerland.<br />
6
ALSACE INTERNATIONAL<br />
Immeuble le Sébastopol<br />
3 quai Kléber<br />
67000 STRASBOURG - FRANCE<br />
Phone: +33 3 88 24 77 68<br />
Fax: +33 3 88 24 77 77<br />
Email: p.h<strong>at</strong>esuer@alsace–intern<strong>at</strong>ional.eu<br />
Contact: P<strong>at</strong>ricia HATESUER<br />
Alsace Intern<strong>at</strong>ional is the economic development agency of the Alsace region.<br />
We accompany intern<strong>at</strong>ional companies interested in doing business in ALSACE’s<br />
BIOVALLEY, the leading trin<strong>at</strong>ional life sciences cluster in Europe.<br />
Alsace Intern<strong>at</strong>ional provides free and confidential customized services for companies<br />
interested in knowing more about doing business in Alsace or in Europe. Services<br />
include loc<strong>at</strong>ion inform<strong>at</strong>ion, grant negoti<strong>at</strong>ions, access to venture capital, business<br />
and scientific contact facilit<strong>at</strong>or, staff integr<strong>at</strong>ion. AI works in close collabor<strong>at</strong>ion with<br />
the ABV network of regional partners.<br />
AI also relies on a network of branch offices worldwide including in the United St<strong>at</strong>es,<br />
Canada, Japan, China, Poland, etc.<br />
ASSISTANCE PUBLIQUE<br />
HÔPITAUX DE PARIS<br />
228 rue du Faubourg Saint-Martin<br />
75010 PARIS - FRANCE<br />
Phone: +33 1 44 84 17 18<br />
Fax: +33 1 44 84 17 00<br />
Email: emanuelle.pascolo@sls.aphp.fr<br />
Web site: http://ottpi.aphp.fr/<br />
Contact: Emanuelle PASCOLO-REBOUILLAT<br />
AP-HP is a public health feder<strong>at</strong>ion for the Paris metropolitan area th<strong>at</strong> g<strong>at</strong>hers<br />
38 hospitals and employs more than 90 000 persons. AP-HP holds a pipeline of almost<br />
400 active p<strong>at</strong>ents in various fields: drug discovery, medical device, gene and cell<br />
therapies, genetics and diagnostics. Through its Office of Technology transfer and<br />
Industrial Partnerships (OTT&PI), AP-HP has successfully developed an active policy<br />
of technology transfer and valu<strong>at</strong>ion of the innov<strong>at</strong>ions stemming from its medical and<br />
research teams.<br />
7
ATLANPOLE<br />
BIOTHERAPIES<br />
95 route de Gachet<br />
Parc de la Chantrerie<br />
44307 NANTES Cedex 3 - FRANCE<br />
Phone: +33 2 40 25 27 20<br />
Fax: +33 2 40 25 10 88<br />
Web site: www.<strong>at</strong>lanpolebiotherapies.com<br />
Contact: Gregory BAUER<br />
For pharmaceutical companies looking for high level partners devoted to healthcare<br />
and biotech, Atlanpole Biotherapies is a cluster th<strong>at</strong> draws together a community<br />
of innov<strong>at</strong>ive companies, fundamental & clinical research organiz<strong>at</strong>ions and higher<br />
educ<strong>at</strong>ion institutions, all loc<strong>at</strong>ed in Western France. Atlanpole Biotherapies gives you<br />
access to extended skills, from biodiagnostics to biomedicine in 4 major areas: cell &<br />
gene therapy, immunology (tumor vaccin<strong>at</strong>ion and transplant<strong>at</strong>ion), biom<strong>at</strong>erials and<br />
radiopharmaceuticals.<br />
AUVERGNE BIOCLUSTER<br />
Centre Delille - Place Delille<br />
63058 CLERMOND FERRAND Cedex 1<br />
FRANCE<br />
Phone: +33 4 73 31 84 45<br />
Fax: +33 4 73 31 84 00<br />
Email: s.lopez@arde-auvergne.com<br />
Web site: www.investir-en-auvergne.com<br />
Contact: Sonia LOPEz<br />
The Regional Economic Development Agency for Auvergne objective is to structure<br />
and promote the region’s talents in biotechnologies. One main mission: to canvass<br />
successful companies in a position to develop investment projects in Auvergne and to<br />
help them set up in the region.<br />
8
BIOCITECH<br />
102 avenue Gaston Roussel<br />
93230 ROMAINVILLE - FRANCE<br />
Phone: +33 1 49 91 31 05<br />
Fax: +33 1 49 91 31 03<br />
Email: jf.boussard@biocitech.com<br />
Web site: www.biocitech.com<br />
Contact: Jean-François BOUSSARD<br />
The Biocitech technology park for life sciences, loc<strong>at</strong>ed on the outskirts of Paris,<br />
offers a world-class environment and services for the development of biotechnology,<br />
biopharmaceutical and fine chemical companies. It is priv<strong>at</strong>ely owned and provides<br />
secure premises and comprehensive facilities based on the l<strong>at</strong>est technology.<br />
Companies can use one or many of the services offered. These include offices,<br />
labor<strong>at</strong>ories and a range of technical and scientific services. Companies already<br />
established <strong>at</strong> Biocitech represent a wide variety of complementary disciplines and<br />
many are working on collabor<strong>at</strong>ive projects. Biocitech is strongly involved in the<br />
development of Paris Region Bio cluster. Along with other organiz<strong>at</strong>ions in the Ilede-France<br />
region around Paris, Biocitech plays a key role in the Medicen Paris Region<br />
network.<br />
BIOPÔLE<br />
CLERMONT-LIMAGNE<br />
Biopôle Clermont-Limagne<br />
63360 SAINT-BEAUzIRE - FRANCE<br />
Phone: +33 4 73 64 43 43<br />
Fax: +33 4 73 64 43 44<br />
Email:<br />
herve.prevoteau@biopole-clermont.com<br />
Web site: www.biopole-clermont.com<br />
Contact: Hérvé PREVOTEAU<br />
The Biopôle Clermont-Limagne was one of the first European technology parks fully<br />
dedic<strong>at</strong>ed to hosting and supporting bio-tech businesses.<br />
It offers bio entrepreneurs an extensive range of tools aimed <strong>at</strong> enhancing business<br />
cre<strong>at</strong>ion and development: cre<strong>at</strong>ion support, networks and funding, accommod<strong>at</strong>ion<br />
and services.<br />
The Biopôle Clermont-Limagne is an interactive pl<strong>at</strong>form for professionals of the<br />
life sciences sector. It encourages collabor<strong>at</strong>ive networking between companies,<br />
research centers, professional associ<strong>at</strong>ions, sciences parks and economic development<br />
organiz<strong>at</strong>ions.<br />
9
BRETAGNE<br />
INTERNATIONAL<br />
Parc Eolys - 16 C rue Jouanet - CS 20834<br />
35708 RENNES Cedex 7 - FRANCE<br />
Phone: +33 2 99 25 04 04<br />
Fax: +33 2 99 25 04 00<br />
Email:<br />
bretagne@bretagne-intern<strong>at</strong>ional.com<br />
Contact: Adrienne GENTIL<br />
Bretagne Intern<strong>at</strong>ional is a non-profit associ<strong>at</strong>ion commissioned by the Regional<br />
Government of Bretagne (Western part of France) to:<br />
• assist Breton companies in their intern<strong>at</strong>ional development<br />
• identify projects of investment in Bretagne and support foreign investors.<br />
Relying on our excellent knowledge of companies ‘ know-how and economic structure<br />
in our region, we can assist YOU with free and confidential assistance through<br />
the different stages of your project to cre<strong>at</strong>e or acquire a company in Bretagne:<br />
d<strong>at</strong>a collection, identific<strong>at</strong>ion of and introduction to potential partners, proposals of<br />
loc<strong>at</strong>ions, assistance before, during and after the install<strong>at</strong>ion…<br />
CANCER BIO SANTÉ<br />
5 avenue Irène Joliot-Curie<br />
31100 TOULOUSE - FRANCE<br />
Phone: +33 5 34 25 50 40<br />
Fax: +33 5 34 25 50 41<br />
Email: contact@cancerbiosante.fr<br />
Web site: www.cancerbiosante.fr<br />
Contact: Céline BEDJA<br />
Cancer-Bio-Santé Cluster, loc<strong>at</strong>ed in Toulouse, is the <strong>French</strong> cluster in France<br />
fully dedic<strong>at</strong>ed to the fight against Cancer, throughout a broad continuum approach<br />
involving prevention, diagnostics, therapeutics and p<strong>at</strong>ient monitoring. CBS supports<br />
companies from the Midi Pyrénées and Limousin regions, which develop innov<strong>at</strong>ive<br />
products in the fields of food & Health, Diagnostics, Biomarkers, Nanotechnologies,<br />
Medical Devices, Immunotherapy, Therapeutics, Bioproduction, Biotechnologies and<br />
Telemedicine.<br />
10
CANCER CAMPUS ®<br />
Espace Maurice Tubiana<br />
114 rue Edouard Vaillant<br />
94805 VILLEJUIF - FRANCE<br />
Phone: +33 1 42 11 67 73<br />
Fax: +33 1 42 11 53 11<br />
Email: valerie.helin@cancer-campus.com<br />
Web site: www.cancer-campus.com<br />
Contact: Valérie HELIN<br />
Cancer Campus is the Paris biocluster dedic<strong>at</strong>ed to cancer innov<strong>at</strong>ion and<br />
brings together, on a specific <strong>at</strong>tracting place, next door to the largest European<br />
comprehensive cancer center (Institut Gustave Roussy), all the first-r<strong>at</strong>e skills to<br />
reach the best of innov<strong>at</strong>ion in all aspects of oncology. Our first building will open in<br />
September 2011 and will be dedic<strong>at</strong>ed to biotechs which will have access to the st<strong>at</strong>eof-the-art<br />
technological pl<strong>at</strong>forms of the Institut Gustave Roussy and of its academic<br />
and clinical partners.<br />
CANCÉROPÔLE CLARA<br />
60 avenue Rockefeller<br />
69008 LYON - FRANCE<br />
Phone: +33 4 37 90 17 15<br />
Fax: +33 4 37 90 27 03<br />
Email: llevy@canceropole-clara.com<br />
Web site: www.canceropole-clara.com<br />
Contact: Laurent LEVY<br />
Cre<strong>at</strong>ed in 2003 by the <strong>French</strong> N<strong>at</strong>ional Cancer Institute (INCa), the Lyon Auvergne<br />
Rhône-Alpes Cancer cluster (CLARA) aims to develop research in oncology in Rhône-<br />
Alpes and Auvergne by associ<strong>at</strong>ing academic, clinical and industrial strengths in order<br />
to develop a regional, n<strong>at</strong>ional and intern<strong>at</strong>ional str<strong>at</strong>egy in the fight against Cancer.<br />
CLARA contributes to the implement<strong>at</strong>ion of partnerships between industrials,<br />
academic and clinical research labor<strong>at</strong>ories to foster technological transfers for the<br />
benefit of p<strong>at</strong>ients.<br />
11
CAPBIOTEK<br />
18 place de la Gare<br />
35000 RENNES - FRANCE<br />
Phone: +33 2 99 67 71 15<br />
Email: bmonks@bretagne-innov<strong>at</strong>ion.fr<br />
Web site: www.capbiotek.fr<br />
Contact: Brian MONKS<br />
Capbiotek, the Bretagne biocluster where n<strong>at</strong>ure meets innov<strong>at</strong>ion.<br />
Thanks to Bretagne’s exceptional marine and agricultural resources, a unique<br />
greentech environment, a world-class agrifood industry, high-level technological<br />
expertise and academic firepower, Bretagne has become a major player in biotech in<br />
France and in Europe as a whole.<br />
COMMUNAUTÉ URBAINE<br />
DU GRAND TOULOUSE<br />
Le Grand Toulouse<br />
Department of Economic Development<br />
6 rue Renée Leduc - BP 35821<br />
31505 TOULOUSE Cedex 5 - FRANCE<br />
Phone: +33 5 81 91 72 11<br />
Fax: +33 5 81 91 72 03<br />
Email: odile.rouillard@grandtoulouse.fr<br />
Web site: www.grandtoulouse.fr<br />
Contact: Odile ROUILLARD<br />
The “Grand Toulouse” Urban community brings together 37 towns and 703 000<br />
inhabitants. Toulouse is the 4 th largest city in France and one of the most <strong>at</strong>tractive<br />
cities in Europe. The “Grand Toulouse” Toulouse is hosting 3 competitiveness clusters,<br />
Aerospace Valley, Cancer Bio Health, Agrimip Innov<strong>at</strong>ion and develops majors projects.<br />
Toulouse is one of the leading regions in Europe for research and development<br />
- 500 labor<strong>at</strong>ories - 20 000 employees in research, 100 000 students - with an<br />
ambitious project, The Toulouse Cancéropôle, a campus dedic<strong>at</strong>ed to the fight against<br />
cancer, combining the strength of innov<strong>at</strong>ive public and priv<strong>at</strong>e sector.<br />
12
CRITT SANTÉ BRETAGNE<br />
2 avenue du Pr Léon Bernard - CS 34317<br />
35043 RENNES Cedex - FRANCE<br />
Phone: +33 2 23 23 45 81<br />
Fax: +33 2 23 23 45 86<br />
Email: jocelyne.leseyec@critt-sante.fr<br />
or contact@critt-sante.fr<br />
Web site: www.critt-sante.fr<br />
Contact: Jocelyne LE SEYEC<br />
CRITT Santé Bretagne works for research units and companies involved in the R&D of<br />
health-care applic<strong>at</strong>ions in Western France. Our missions are to develop and support<br />
partnerships, to provide technological assistance, to assist project leaders and to<br />
promote development of SMEs.<br />
Our fields of expertise include:<br />
1) Medical devices, medical imaging, health technologies<br />
2) Nutrition for human health and<br />
3) Biotechnology, drug development, new therapies. We particip<strong>at</strong>e to Capbiotek,<br />
the Bretagne biocluster.<br />
ESSONNE CHAMBER OF<br />
COMMERCE & INDUSTRY<br />
2 cours Monseigneur Roméro<br />
BP 135 - 91004 EVRY - FRANCE<br />
Phone: +33 1 60 79 90 74<br />
Fax: +33 1 60 79 90 71<br />
Email:<br />
rel<strong>at</strong>ions.intern<strong>at</strong>ionales@essonne.cci.fr<br />
Web site: www.essonne.cci.fr<br />
Contact: Marianne SASSERANT<br />
The Essonne Chamber of Commerce & Industry represents the general interests<br />
of Industry & commerce, promotes the companies of its district localy as well as<br />
intern<strong>at</strong>ionally. Through the Boston office Hubtech21, it provides specialized services<br />
in helping technology companies establish & grow their business in trans<strong>at</strong>lantic<br />
markets efficiently. We provide clients in the Life Sciences with a range of customized<br />
service solutions, from pre-market prospecting and logistics services, to full<br />
oper<strong>at</strong>ional support (market intelligence, Development str<strong>at</strong>egies, sales support…).<br />
BOSTON OFFICE: One Broadway 14 th floor-Cambrige, MA 02142- USA - Tel:+ 617 583<br />
1350 hubtech21@hubtech21.com<br />
13
ESSONNE<br />
SOUTH PARIS REGION<br />
6 Cours Monseigneur Roméro<br />
91025 EVRY - FRANCE<br />
Phone: +33 1 69 91 42 56<br />
Fax: +33 1 69 91 17 81<br />
Email: caroline.mercier@essonnedeveloppement.com<br />
Web site: www.essonne-developpement.com<br />
Contact: Caroline MERCIER<br />
You want to: Grow your sales in EU and reach <strong>French</strong> and European customers? Form<br />
a EU subsidiary within deadline and budget? Recruit key staff? Get in touch with<br />
str<strong>at</strong>egic partners and service providers?<br />
We can help you to: Get tailor-made services to solve your development problems;<br />
Save time: a dedic<strong>at</strong>ed manager is in charge of your whole project. Save money:<br />
Essonne services are free of charge and confidential; Lower risks in setting up in<br />
France: Essonne makes you benefit from its networks to start oper<strong>at</strong>ions as efficiently<br />
as possible.<br />
EUROBIOMED<br />
C/ CMCI - 2 rue Henri Barbusse<br />
13001 MARSEILLE - FRANCE<br />
Phone: +33 4 91 13 74 65<br />
Fax: +33 4 91 13 74 66<br />
Email: contact@eurobiomed.org<br />
Web site: www.eurobiomed.org<br />
Contact: Emilie ROYèRE<br />
Eurobiomed is accredited by the french government as a competitiveness<br />
cluster. Eurobiomed feder<strong>at</strong>es more than 400 healthcare stakeholders along the<br />
Mediterranean border in the south of France. Our main missions are to develop and<br />
feder<strong>at</strong>e the network in order to boost the development of partnerships; to provide<br />
business support to companies via the implement<strong>at</strong>ion of services, tools and access<br />
to funding; to highlight the excellence of both academic and industrial healthcare<br />
research performed in the South of France; to ease the access to public fundings for<br />
collabor<strong>at</strong>ive R&D projects.<br />
14
GENOPOLE<br />
GENOPOLE Campus 1<br />
5 rue Henri Desbrueres<br />
91030 EVRY - FRANCE<br />
Phone: +33 1 60 87 83 12<br />
Fax: +33 1 60 87 83 01<br />
Email: gabriel.mergui@genopole.fr<br />
Contact: Gabriel MERGUI<br />
GENOPOLE is France’s leading biopark dedic<strong>at</strong>ed to biotech & genetics research. It<br />
brings together priv<strong>at</strong>e and academic labs, biotech companies and higher educ<strong>at</strong>ion<br />
facilities (University of Evry Val d’Essonne) on a 90,000 sqm site. With 20 research labs<br />
and a portfolio of over 70 biotech firms, therapeutic innov<strong>at</strong>ion is a key concern for<br />
Genopole stakeholders. Genopole’s objective is to reinforce technology transfer to the<br />
industrial sector; cre<strong>at</strong>e and m<strong>at</strong>ure biotech companies.<br />
LILLE EURASANTÉ<br />
Parc Eurasanté<br />
310 avenue Eugène Avinée<br />
59120 LOOS - FRANCE<br />
Phone: +33 3 28 55 90 60<br />
Fax: +33 3 28 55 90 61<br />
Email: crondel@eurasante.com<br />
Web site: www.eurasante.com<br />
Contact: Christelle RONDEL<br />
Eurasanté, the Economic Development Agency dedic<strong>at</strong>ed to healthcare, nutrition and<br />
biotech activities in Northern France, promotes the Lille cluster and the Bio Business<br />
Park where 120 health, nutrition & biotech companies are settled within the largest<br />
European university hospital complex. We assist firms in setting-up in Northern<br />
France.<br />
15
LYON CHAMBER OF<br />
COMMERCE AND INDUSTRY<br />
Place de la Bourse<br />
69289 LYON Cedex 02 - FRANCE<br />
Phone: +33 4 72 40 57 28<br />
Fax: +33 4 72 40 57 61<br />
Email: hours@lyon.cci.fr<br />
Web site: www.lyon.cci.fr<br />
Contact: Julie-Capucine HOURS ROUSSILLE<br />
The Lyon Chamber of Commerce and Industry is a public organis<strong>at</strong>ion. Its mission<br />
is to:<br />
• lobby the public authorities in the interest of companies and retailers in its district<br />
• promote Lyon’s advantages, <strong>at</strong>tract inward investment and newcomer businesses<br />
• assist companies, retailers and service businesses in every stage of their<br />
development<br />
• build and manage facilities needed for local economic development.<br />
The Lyon CCI’s intern<strong>at</strong>ional department provides local <strong>French</strong> companies with<br />
intern<strong>at</strong>ional development consulting by giving economic, str<strong>at</strong>egic, tax and legal<br />
advice for integr<strong>at</strong>ing foreign markets.<br />
LYONBIOPOLE<br />
Bâtiment Domilyon<br />
321 avenue Jean Jaurès<br />
69007 LYON - FRANCE<br />
Phone: +33 4 72 76 53 30<br />
Fax: +33 4 72 70 48 29<br />
Email: isabelle.scarabin@lyonbiopole.com<br />
Web site: www.lyonbiopole.com<br />
Contact: Isabelle SCARABIN<br />
Lyonbiopole is a <strong>French</strong> BIO Cluster loc<strong>at</strong>ed in the Rhone-Alpes Region (Lyon-<br />
Grenoble area) and focused on human/animal infectious diseases, immune disorders<br />
and cancers.<br />
Lyonbiopole is your str<strong>at</strong>egic partner in France to: - Develop your network and identify<br />
str<strong>at</strong>egic partners – Innov<strong>at</strong>e and set-up R&D projects - Gain access to public and<br />
priv<strong>at</strong>e funds - Settle your activity in fully equipped pl<strong>at</strong>form of excellence (BSL2/BSL3<br />
Labs, dedic<strong>at</strong>ed bioproduction & bioanalyses facilities, etc.).<br />
16
MEDICEN PARIS REGION<br />
6 rue Alexandre Cabanel<br />
75015 PARIS - FRANCE<br />
Phone: +33 1 44 49 30 00<br />
Fax: +33 1 44 49 30 05<br />
Email: medicen@medicen.org<br />
Web site: www.medicen.org<br />
Contact: François CHEVILLARD<br />
Medicen Paris Region is a cluster which unites all key life science and healthcare<br />
players in the Paris metropolitan area, France.The cluster’s top priorities are to<br />
cre<strong>at</strong>e a cluster environment fostering the development of the health sector in<br />
the Paris Region, to promote growth of its companies and to develop n<strong>at</strong>ional and<br />
intern<strong>at</strong>ional partnerships to increase the cluster’s and the Paris Region’s notoriety<br />
and <strong>at</strong>tractiveness.<br />
The Medicen Paris Region’s R&D str<strong>at</strong>egy is based on: transl<strong>at</strong>ional medicine,<br />
biological tools for industrial use and bio-therapeutic products, biodigital technology<br />
(bio-computing, integr<strong>at</strong>ion and modelling, e-health, brain-machine interface<br />
technology).<br />
MONTPELLIER<br />
AGGLOMÉRATION<br />
50 place zeus – CS 39556<br />
34961 MONTPELLIER Cedex 2 - FRANCE<br />
Phone: +33 4 67 13 61 20<br />
Fax: +33 4 67 13 61 10<br />
Email: t.asteriou@montpellier-agglo.com<br />
Web site: www.montpellier-technopole.com<br />
Contact: Trias ASTERIOU<br />
The life sciences sector is one of the driving factors in the Montpellier (France) economy.<br />
Montpellier is a city with a long tradition in medicine with more than 120 public<br />
sector and priv<strong>at</strong>e research labor<strong>at</strong>ories, several leading intern<strong>at</strong>ional companies<br />
(sanofi aventis, BioRad, Horiba Medical, Bausch & Lomb…) and an important tissue<br />
of innov<strong>at</strong>ive SMEs. Euromédecine Biopôle, 21,000 sq.m of offices and labor<strong>at</strong>ories<br />
dedic<strong>at</strong>ed to life sciences companies (10,500 sq.m already delivered). Montpellier<br />
Intern<strong>at</strong>ional Business Incub<strong>at</strong>or: A 3,500 m² building for foreign companies with soft<br />
landings services.<br />
17
ONLYLYON ADERLY<br />
Place de la Bourse<br />
69002 LYON - FRANCE<br />
Phone: +33 4 72 40 81 98<br />
Email: delumley@aderly.com<br />
Web site: www.aderly.com<br />
Contact: Thierry de LUMLEY<br />
ADERLY’s key strength is to provide a customized business development service. This<br />
includes one-to-one meetings with potential customers, R&D partners and key opinion<br />
leaders, as well as lawyers, accountants, public investors, venture capitalists and<br />
business angels. In Lyon, join leaders such as Genzyme, Biomérieux, Merial, Becton<br />
Dickinson, Mylan, Covidien, Sanofi-Pasteur, Merck Serono, Integra Life Sciences,<br />
Baxter, Abbott Pharma and Olympus Biotechnology, along with other companies who<br />
have been assisted by ADERLY in the boosting of their European business: Singulex,<br />
Oncotherapy Sciences, Prediction Sciences, CellSeed and more.<br />
ONLYLYON<br />
GREATER LYON<br />
20 rue du lac - BP 3103<br />
69399 LYON Cedex 03 - FRANCE<br />
Phone: +33 4 78 63 42 31<br />
Fax: +33 4 26 99 38 74<br />
Email: clab<strong>at</strong>@grandlyon.org<br />
Web site:<br />
www.entreprendre @grandlyon.org<br />
Contact: Clémence LABAT<br />
Through its partnership-based approach, Gre<strong>at</strong>er Lyon <strong>at</strong>tracts year after year more<br />
investors and intern<strong>at</strong>ional business leaders. The skills of the institutional partners<br />
of the Life Sciences are leveraged to <strong>at</strong>tract talent, support innov<strong>at</strong>ion and help<br />
companies start up and develop.<br />
Gre<strong>at</strong>er Lyon financially supports the actions of the Lyonbiopôle competitive cluster<br />
and of the Cancer Center CLARA research cluster, as well as key projects for the urban<br />
area in connection with the Life Sciences.<br />
18
PARIS CHAMBER OF COMMERCE<br />
AND INDUSTRY<br />
Bourse de Commerce<br />
2 rue de Viarmes<br />
75001 PARIS - FRANCE<br />
Phone: +33 1 55 65 35 13<br />
Fax: +33 1 55 65 35 85<br />
Email: ipottier@ccip.fr<br />
Web site: www.intern<strong>at</strong>ional.ccip.fr<br />
Contact: Isabelle POTTIER<br />
Paris area is a leading region as far as Life Sciences are concerned. The Paris Chamber<br />
of Commerce and Industry provides customized services for companies interested in<br />
doing business <strong>at</strong> an intern<strong>at</strong>ional level. We assist them in finding potential partners<br />
and opportunities abroad.<br />
The Paris Chamber of Commerce and Industry strongly supports Life Sciences as a<br />
leading industry. We work with the Paris Region Life Sciences cluster: Medicen Paris<br />
Region.<br />
PARIS REGION ECONOMIC<br />
DEVELOPMENT AGENCY<br />
3 rue des Saussaies<br />
75008 PARIS - FRANCE<br />
Phone: +33 1 58 18 69 00<br />
Fax: +33 1 58 18 69 71<br />
Email: lcurti@paris-region.com<br />
Web site: www.paris-region.com<br />
Contact: Laurence CURTI<br />
If you are interested in doing business in Paris Region, Paris Region Economic<br />
Development Agency is here to help you. With a core of recognized skills and an<br />
effective network of experience, the agency’s mission is to support your projects:<br />
informing you (tax<strong>at</strong>ion issues, purchase and rental costs…), advising you (setting up<br />
your new company, loc<strong>at</strong>ion offices…), and supporting you (setting up technology and<br />
marketing partnerships, support for exp<strong>at</strong>ri<strong>at</strong>es…).<br />
19
PROVENCE PROMOTION<br />
Les Docks Atrium 10.5<br />
10 place de la Joliette<br />
13002 MARSEILLE - FRANCE<br />
Phone: +33 4 96 11 60 00<br />
Fax: +33 4 96 11 60 11<br />
Email: m.vis@provence-promotion.fr<br />
Web site: www.theprovencepartnership.com<br />
Contact: M<strong>at</strong>thieu VIS<br />
Provence Promotion is the Official Inward Investment agency of Marseille-Provence<br />
area, South of France.<br />
We assist free of charge companies reloc<strong>at</strong>e and/or develop their business in our<br />
Mediterranean region, which has become a str<strong>at</strong>egic destin<strong>at</strong>ion for biotechnology<br />
companies.<br />
Provence hosts worldwide known academic labor<strong>at</strong>ories like the Luminy Immunology<br />
centre CIML, the infectious disease University Hospital Institute led by Pr Raoult, or<br />
the oncology research institute of Paoli-Calmettes, one of France’s most concentr<strong>at</strong>ed<br />
networks of hospital/university structures with important drug development activities,<br />
as well as leading firms such as Inn<strong>at</strong>e Pharma, Ipsogen, Supersonic Imagine,<br />
Provepharm, Trophos…<br />
The Provence Partnership is your unique partner for building and growing your<br />
business in Provence.<br />
PROLOGUE BIOTECH<br />
SICOVAL<br />
Rue Pierre et Marie Curie - BP 28262<br />
31682 LABEGE Cedex - FRANCE<br />
Phone: +33 5 61 28 70 00<br />
Fax: +33 5 61 28 70 01<br />
Email: prologue.biotech@sicoval.fr<br />
Web site: www.sicoval.fr<br />
Prologue Biotech is a life science company incub<strong>at</strong>or th<strong>at</strong> currently hosts and supports<br />
9 incorpor<strong>at</strong>ed companies (Ambiotis, Genticel, Cerenis Therapeutics, Antabio, Synelvia,<br />
Icelltis, Physiogenex, Urosphere, Vectalys). In the heart of Toulouse-Labege-Innopole<br />
biopark, Prologue Biotech offers tailored facilities (1000 M 2 labor<strong>at</strong>ories, 250 m 2 offices),<br />
services (animal facility, washing area, on-line scientific document<strong>at</strong>ion, 4°C and<br />
37°C stores, etc.), business development guidance and administr<strong>at</strong>ive support by an<br />
experienced team, and privileged access to available and upcoming biotech buildings.<br />
20
TEAM COTE D’AZUR<br />
400 Promenade des Anglais - BP 3185<br />
06204 NICE Cedex 3 - FRANCE<br />
Phone: +33 4 92 17 51 85<br />
Fax: +33 4 93 80 05 76<br />
Email: cjacquet@teamcotedazur.fr<br />
Web site: www.investincotedazur.com<br />
Contact: Céline JACQUET<br />
Team Côte d’Azur is the Côte d’Azur economic development agency.<br />
Team Côte d’Azur provides companies with assistance rel<strong>at</strong>ed to a precise evalu<strong>at</strong>ion<br />
of wh<strong>at</strong> Nice and Sophia Antipolis science and technology park can offer with regard to<br />
your investment project, free and confidential assistance in preparing your setting-up<br />
file (feasibility study, identific<strong>at</strong>ion and follow-up of eligible financial support, transfer<br />
of teams to the area, essential networking, etc.)<br />
TECHNOPOLE-CBS<br />
Hôtel d’entreprises<br />
Parc d’activités des Saules<br />
27100 VAL DE REUIL - FRANCE<br />
Phone: +33 2 32 25 59 59<br />
Fax: +33 2 32 25 59 60<br />
Email: pbrottier@technopole-cbs.com<br />
Web site: www.technopole-cbs.com<br />
Contact: Philippe BROTTIER<br />
Support and network the stakeholders in the Chemistry-Biology-Health industry:<br />
Develop discussions and collabor<strong>at</strong>ive undertakings between public research and<br />
industry oper<strong>at</strong>ors in a wide range of fields; Foster the cre<strong>at</strong>ion of innov<strong>at</strong>ive activities<br />
in the region by identifying business cre<strong>at</strong>ion projects from academic research;<br />
Promote Haute-Normandie by publicising the available research potential in the<br />
region, the welcome services <strong>at</strong> industry specific business parks and the industrial<br />
environment, <strong>at</strong> conferences, trade fairs and other events.<br />
21
UNIVERSITÉ DE LYON<br />
LYON SCIENCE TRANSFERT<br />
37 rue du Repos<br />
69361 LYON - FRANCE<br />
Phone: +33 6 82 90 86 18<br />
Fax: +33 4 37 37 26 71<br />
Email: sandrine.carteau@universite-lyon.fr<br />
Web site: www.universite-lyon.fr/lst<br />
Contacts: Sandrine CARTEAU<br />
Christian MALLY<br />
Université de Lyon is a feder<strong>at</strong>ion of 18 Higher Educ<strong>at</strong>ion and research Institutes.<br />
It is strong of 230 research labor<strong>at</strong>ories, 120000 students, 5000 PhD students and<br />
11500 researchers. The Technology Transfer Office, named Lyon Science Transfert<br />
(LST), supports the Université de Lyon by transferring basic research discoveries<br />
made in the labor<strong>at</strong>ories to the marketplace for commercial development. Lyon<br />
Science Transfert offers numerous technologies on drug discovery, diagnostic, vaccine<br />
production, etc.<br />
22
COMPANIES
ADOCIA<br />
115 avenue Lacassagne<br />
69003 LYON - FRANCE<br />
Phone: +33 4 72 610 610<br />
Fax: +33 4 72 36 39 67<br />
Email: o.soula@adocia.com<br />
Web site: www.adocia.com<br />
Contact: Olivier SOULA<br />
Adocia is a protein delivery company. Its proprietary innov<strong>at</strong>ive technology<br />
BioChaperone ® has been applied to growth factors for regener<strong>at</strong>ive medicine and<br />
to insulin and monoclonal antibodies for chronic diseases. Adocia has completed<br />
successfully a phase I for fast-acting human insulin and is currently evalu<strong>at</strong>ing a<br />
spray on 200 p<strong>at</strong>ients suffering from diabetic foot ulcer. Up to now Adocia has raised<br />
28M€ and is collabor<strong>at</strong>ing with 3 pharmaceutical companies.<br />
AEPODIA<br />
La Grande Arche - Paroi Nord<br />
92044 PARIS-LA DÉFENSE - FRANCE<br />
Phone: +33 1 40 90 30 14<br />
Email: info@aepodia.com<br />
Web site: www.aepodia.com<br />
Contact: Stéphanie ALVAREz LOUzAN<br />
Aepodia is experienced and specialized in Early Phase Clinical Development<br />
and Clinical Pharmacology studies. This strong pharmacological, scientific and<br />
study design background is a gre<strong>at</strong> asset to make well balanced (value/cost/time)<br />
recommend<strong>at</strong>ions regarding potential studies to be done in view of the new legisl<strong>at</strong>ion<br />
for health and nutrition claims. In collabor<strong>at</strong>ion with you, Aepodia provide ad hoc<br />
services like coordin<strong>at</strong>ion and monitoring of your study, st<strong>at</strong>istical support, prepar<strong>at</strong>ion<br />
and writing of clinical study protocols and lastly scientific reports and public<strong>at</strong>ions to<br />
support the claim or p<strong>at</strong>ent.<br />
24
AFFILOGIC<br />
c/o UMR 6204<br />
Faculté des Sciences<br />
2 rue de la Houssinière<br />
44000 NANTES - FRANCE<br />
Phone: +33 6 25 80 73 65<br />
Email: olivier@affilogic.com<br />
Web site: www.affilogic.com<br />
Contact: Olivier KITTEN<br />
Affilogic develops custom affinity ligands for bioprocessing, analytics, diagnostics &<br />
therapeutic applic<strong>at</strong>ions.<br />
Affilogic ligands, a.k.a. Nanofitins, are highly stable, easy to manufacture and perform<br />
like mAbs in selected applic<strong>at</strong>ions.<br />
The company is providing custom development of specific Nanofitins and is looking for<br />
partners to co-develop applic<strong>at</strong>ions in Point of Care.<br />
ALAXIA<br />
3-11 rue de la Perlerie<br />
69120 Vaulx en Velin - FRANCE<br />
Phone: +33 4 72 81 09 26<br />
Fax: +33 4 78 41 17 19<br />
Email: philippe.bordeau@bioalaxia.eu<br />
Web site: www.alaxia-pharma.eu<br />
Contact: Philippe BORDEAU<br />
Alaxia, a drug discovery company, develops airway therapeutic solutions for respir<strong>at</strong>ory<br />
diseases based on its own peroxidase pl<strong>at</strong>e form. Its Meveol product, 1 st product<br />
exiting the pipeline, has been recognized Orphan medicinal product for cystic fibrosis<br />
condition by both EMA & FDA. Meveol is both an antimicrobial and anti-inflamm<strong>at</strong>ory<br />
product, targeting to kills bacteria, including antibiotic resistant strains and to<br />
compens<strong>at</strong>e inn<strong>at</strong>e lung defense system. Seeking for COPD, URTI, LRTI partnership.<br />
25
ALIZÉ PHARMA<br />
15 Chemin du Saquin<br />
Espace Européen - BAT G<br />
69130 ECULLY - FRANCE<br />
Phone: +33 4 72 18 94 28<br />
Fax: +33 4 78 33 36 29<br />
Email: tabrib<strong>at</strong>@alz-pharma.com<br />
vwesley@alz-pharma.com<br />
Web site: www-alz-pharma.com<br />
Contact: Valérie WESLEY<br />
The Alizé Pharma Group is specialized in the development of innov<strong>at</strong>ive<br />
biopharmaceuticals for the tre<strong>at</strong>ment of metabolic diseases and cancer. Its<br />
management is made up of a team of drug development experts and a board of<br />
directors offering wide intern<strong>at</strong>ional experience. The two main products currently in<br />
development include a ghrelin-derived peptide targeting type II diabetes and other<br />
cardiovascular risks, and a PEGyl<strong>at</strong>ed recombinant L-asparaginase for the tre<strong>at</strong>ment<br />
of acute lymphoblastic leukemia.<br />
ALMETIS<br />
4 rue Boussingault<br />
67000 STRASBOURG - FRANCE<br />
Phone: +33 3 68 85 31 77<br />
Email: contact@almetisbio.com<br />
Web site: www.almetisbio.com<br />
Contact: Marjorie SIDHOUM<br />
Almetis is dedic<strong>at</strong>ed to the discovery and the development of innov<strong>at</strong>ive metal-based<br />
therapeutics in oncology up to proof of concept in man. Our expertise is unique on<br />
organometallic drugs th<strong>at</strong> have demonstr<strong>at</strong>ed anticancer properties answering to<br />
usual drawbacks of chemotherapies and constituting a new class of anticancer drugs.<br />
Our mission is to provide therapeutic solutions to unmet medical needs via innov<strong>at</strong>ive<br />
tre<strong>at</strong>ment triggering specific mechanism. Almetis’ pipeline g<strong>at</strong>hers new chemical<br />
entities from hits to preclinical candid<strong>at</strong>es and is open to develop collabor<strong>at</strong>ive<br />
programs with partners.<br />
26
ALZPROTECT<br />
70 rue du Dr Yersin<br />
59120 LOOS - FRANCE<br />
Phone: +33 3 28 55 50 51<br />
Fax: +33 3 62 02 56 40<br />
Email: contact@alzprotect.com<br />
Web site: www.alzprotect.com<br />
Contact: P. VERWAERDE<br />
Alzprotect is a startup biopharmaceutical company developing small molecule drug for<br />
neurodegener<strong>at</strong>ive diseases. Its lead product, AZP2006, an anti Alzheimer candid<strong>at</strong>e<br />
drug, will enter clinical phase 1 by the end of 2011. Animal proof of concept studies<br />
have shown its unique effect on both APP and Tau p<strong>at</strong>hologies. Alzprotect is developing<br />
in parallel several small molecules against neurodegener<strong>at</strong>ive diseases.<br />
AMATSI<br />
17 Parc des Vautes<br />
34980 SAINT GELY DU FESC - FRANCE<br />
Phone: +33 4 99 58 35 86<br />
Fax: +33 4 99 58 38 61<br />
Email: l.benedicto@am<strong>at</strong>si.com<br />
Web site: www.am<strong>at</strong>si.com<br />
Contact: Lorie BENEDICTO<br />
AMATSI, loc<strong>at</strong>ed <strong>at</strong> Montpellier and Toulouse in France and Cambridge in the USA,<br />
is a Contract Development and Manufacturing Organiz<strong>at</strong>ion (CDMO) specializing in<br />
drug development services. With its strong team of 175 staff (including AVOGADRO’s<br />
people), AMATSI offers expert pharmaceutical development and clinical manufacturing<br />
services to Biotech & Pharmaceutical companies with a specific support for orphan<br />
and paedi<strong>at</strong>ric drug development. Range of expertise: formul<strong>at</strong>ion & analytical<br />
development, PK-ADME studies, bioanalysis, QC, clinical supplies manufacturing,<br />
packaging, storage and logistics, ICH stability study, regul<strong>at</strong>ory & CMC support.<br />
27
ANALGESIA<br />
PARTNERSHIP<br />
Labor<strong>at</strong>oire de Pharmacologie Médicale,<br />
Faculté de Médecine<br />
28 place Henri Dunant<br />
63000 CLERMONT-FERRAND - FRANCE<br />
Phone: +33 4 73 17 82 02<br />
Fax: +33 4 73 27 46 21<br />
Email: contact@AnalgesiaPartnership.com<br />
Web site: www.AnalgesiaPartnership.com<br />
Contact: Alice CORTEVAL<br />
Analgesia Partnership was founded in 2008 as a result of the outstanding dynamism<br />
of academics and businesses driven on the same idea: fostering the bench 1 bedside<br />
Continuum in Pain Innov<strong>at</strong>ion.<br />
This One-Stop-Shop solution offers a pl<strong>at</strong>form of integr<strong>at</strong>ed services focused on pain<br />
profiling and proposes “à la carte” services, custom-tailored for your project and<br />
flexible to adapt to your results.<br />
Academic and priv<strong>at</strong>e experts bringing together their cultures towards innov<strong>at</strong>ion, will<br />
provide you with comprehensive and complementary services from drug discovery to<br />
clinics.<br />
ANIMASCOPE<br />
zA Eurekalp<br />
38660 ST VINCENT DE MERCUzE<br />
FRANCE<br />
Phone: +33 4 76 97 94 87<br />
Fax: +33 9 55 75 39 11 09<br />
Email: d.christiaen@animascope.eu<br />
Web site: www.animascope.eu<br />
Contact: Daniel CHRISTIAEN<br />
Animascope offers customized contract services for multi-modality biomedical<br />
imaging in vivo: protocol design, image acquisition, image processing, image analysis,<br />
reporting. We assist in model sourcing and pre-conditioning. Imaging is suitable for<br />
discovery research, to bridge the gap between preclinical and clinical research, for<br />
phenotyping, model or biomarker valid<strong>at</strong>ion, biodistribution studies, as well as to<br />
assess efficacy and safety in many fields, such as biologics, cardiovascular, gene<br />
and cell therapy, immuniz<strong>at</strong>ion, musculoskeletal, neurology, nephrology, oncology,<br />
reproduction, development, nutrition.<br />
28
ANS BIOTECH - AUVERGNE<br />
NEUROSCIENCES<br />
Biopôle Clermont Limagne<br />
63360 SAINT BEAUzIRE - FRANCE<br />
Phone: +33 4 73 17 82 36<br />
Fax: +33 4 73 17 82 34<br />
Email: francois.caussade@ans-biotech.com<br />
Web site: www.ans-biotech.com<br />
Contact: François CAUSSADE<br />
ANS Biotech, a preclinical CRO dedic<strong>at</strong>ed to pain pharmacology, supports drug<br />
discovery and development efforts of companies involved in human and animal health,<br />
food and nutrition, by providing them with:<br />
• clinically relevant in vivo models for successful R&D of innov<strong>at</strong>ive analgesics,<br />
especially in the field of inflamm<strong>at</strong>ory pain, neurop<strong>at</strong>hic pain and visceral pain<br />
• customized scientific studies meeting drug discovery and development<br />
objectives<br />
• consulting activities.<br />
ARIANA<br />
PHARMACEUTICALS<br />
28 rue du Docteur Finlay<br />
75015 PARIS - FRANCE<br />
Phone: +33 01 44 37 17 00<br />
Fax: +33 01 44 37 17 01<br />
Email: info@arianapharma.com<br />
Web site: www.arianapharma.com<br />
Contact: Mohammad AFSHAR<br />
Ariana, a spin-off of the Institut Pasteur, is a leading decision support and d<strong>at</strong>a<br />
mining company, focused on transforming d<strong>at</strong>a into inform<strong>at</strong>ion to acceler<strong>at</strong>e the<br />
discovery and development of biomarkers and pharmaceutical drugs. Ariana has<br />
developed KEM ® (Knowledge Extraction Management), a proprietary decision support<br />
technology for rapid analysis of multi-parametric / multi-objective d<strong>at</strong>a. KEM is<br />
routinely applied to the identific<strong>at</strong>ion of Biomarkers, optimiz<strong>at</strong>ion in drug discovery,<br />
analysis of clinical d<strong>at</strong>a and early signal detection in drug safety.<br />
29
ATLANTIC BONE SCREEN<br />
1 rue Gaston Veil<br />
44035 NANTES Cedex 1 - FRANCE<br />
Phone: +33 2 40 41 11 25<br />
Fax: +33 2 40 41 28 35<br />
Email:<br />
morgane.bellus@<strong>at</strong>lantic-bone-screen.com<br />
Web site: www.<strong>at</strong>lantic-bone-screen.com<br />
Contact: Morgane BELLUS<br />
ATLANTIC BONE SCREEN is a french CRO focusing on bone and joint diseases and<br />
more particularly on bone diseases from tumor origin.<br />
Our company puts <strong>at</strong> its customers’ disposal a unique preclinical pl<strong>at</strong>form with a<br />
wide range of competitive in vitro and in vivo assays as well as histology and imaging<br />
services. This pl<strong>at</strong>form permits the detection, the evalu<strong>at</strong>ion and the scientific<br />
valid<strong>at</strong>ion of compounds presenting an interest <strong>at</strong> bone and joint level.<br />
AVOGADRO<br />
Parc de Génibr<strong>at</strong><br />
31470 FONTENILLES - FRANCE<br />
Phone: +33 5 62 14 73 14<br />
Fax: +33 5 62 14 73 10<br />
Email: avogadro@avogadro.fr<br />
Web site: www.avogadro-lab.com<br />
Contact: Marie-Christine BODINIER<br />
AVOGADRO / AMATSI: Toulouse - Montpellier, France & Cambridge, MA, USA.<br />
AVOGADRO / AMATSI (175 scientists) offers a wide range of services to its clients in<br />
the following fields:<br />
• pharmaceutical development (pre-formul<strong>at</strong>ion, formul<strong>at</strong>ion, analytical development,<br />
stability studies)<br />
• pre-clinical development (bioanalysis, PK, ADME, biochemistry, residues and TAS)<br />
• manufacturing, packaging, storage & distribution of clinical b<strong>at</strong>ches<br />
• quality control (raw m<strong>at</strong>erials and finished products).<br />
Our services are undertaken in a GLP and GMP assured environment (EMA, FDA)<br />
maintaining our core values (reactivity, flexibility and communic<strong>at</strong>ion).<br />
30
BIOFILM CONTROL<br />
Biopôle Clermont-Limagne<br />
63360 SAINT-BEAUzIRE - FRANCE<br />
Phone: +33 4 73 33 39 80<br />
Email: pascal.mayer@biofilmcontrol.com<br />
Web site: www.biofilmcontrol.com<br />
Contact: Pascal MAYER<br />
We leverage our unique and proprietary biological assays in order to be the first to<br />
discover compounds for fighting bacterial biofilms involved in triggering and sustaining<br />
severe and common human diseases.<br />
Our initial therapeutic targets are <strong>at</strong>opic derm<strong>at</strong>itis, acne, rhinosinusitis and pressure<br />
ulcers, each addressing a multi-billion Euro market.<br />
Our initial screening campaign with a focus on staphylococci has already identified<br />
a first set of active compounds with a promising chemical p<strong>at</strong>tern which we are now<br />
pushing into hit-to-lead and preclinical processes.<br />
BIO-MODELING SYSTEMS<br />
26 rue Saint Lambert<br />
75015 PARIS - FRANCE<br />
Phone: +33 6 83 06 12 72<br />
Email: manuel.gea@bmsystems.net<br />
Web site: www.bmsystems.net<br />
Contact: Manuel GEA<br />
BMSystems, is the first and to d<strong>at</strong>e the only systems biology company th<strong>at</strong> succeeded<br />
to cre<strong>at</strong>e in-silico heuristic models valid<strong>at</strong>ed in-vivo th<strong>at</strong> led to discoveries, p<strong>at</strong>ents,<br />
or oper<strong>at</strong>ional businesses through its innov<strong>at</strong>ive business model, in the fields of<br />
infectious diseases, neurology, psychi<strong>at</strong>ry, oncology and industrial biotech.<br />
Cre<strong>at</strong>ed in 2004, profitable since 2006, BMSystems is involved in the development its<br />
second spin-off in psychi<strong>at</strong>ric disorders after the success of its first one, Pherecydes-<br />
Pharma, in infectious diseases.<br />
31
BIOSIMS TECHNOLOGIES<br />
SEINE BIOPOLIS<br />
70 route de Lyons la forêt<br />
76000 ROUEN - FRANCE<br />
Phone: +33 2 76 08 60 24<br />
Fax: +33 2 35 52 93 33<br />
Email: christine.heuclin@biosims.fr<br />
Web site: www.biosims.fr<br />
Contact: Christine HEUCLIN<br />
BioSIMS has developed a unique Digital Protein Microarray Technology, which is a<br />
powerful research tool for low abundance targets in low volume samples. We are<br />
a specialized contract research organiz<strong>at</strong>ion, providing innov<strong>at</strong>ive solutions for<br />
detecting biomolecules and small chemical compounds, by using Secondary Ions<br />
Mass spectrometry (SIMS): the most sensitive of all the commonly used analytical<br />
techniques.<br />
The company’s objective is to develop new business opportunities in the biomarkers<br />
field with biotech and/ or pharmaceutical companies.<br />
BIOTRIAL<br />
7-9 rue Jean-Louis Bertrand<br />
35000 RENNES - FRANCE<br />
Phone: +33 2 99 59 91 91<br />
Fax: +33 2 99 59 91 97<br />
Email: damien.pillon@biotrial.co.uk<br />
Web site: www.biotrial.com<br />
Contact: Damien PILLON<br />
Founded in 1989, Biotrial is a leading full-service provider specialized in Early<br />
Development with a large range of services from Non-Clinical Pharmacology, Phase I<br />
studies, Phase II-IV Trial Management, Oncology, D<strong>at</strong>a Management, Biost<strong>at</strong>istics,<br />
ECG & Imaging Core Lab, Regul<strong>at</strong>ory Affairs to Medical Writing. Based in France<br />
(Paris & Rennes), the United Kingdom (London), and Belgium (Brussels), with an<br />
intern<strong>at</strong>ional team of 250 people, Biotrial performs hundreds of studies a year and<br />
offers tailor-made solutions to Pharma and Biotech companies. For 2011, Biotrial is<br />
pleased to announce a doubling of research capacity in Rennes, an increase in beds<br />
in the Paris Unit, a sales presence in Belgium and the disclosure of the site for the US<br />
Phase I Clinic.<br />
32
CABINET REGIMBEAU<br />
139 rue Vendôme<br />
69477 LYON Cedex 06 - FRANCE<br />
Phone: +33 4 72 83 85 70<br />
Fax: +33 4 78 24 30 78<br />
Email: tetaz@regimbeau.eu<br />
Web site: www.regimbeau.eu<br />
Contact: Franck TETAz<br />
Regimbeau Industrial Property Law Firm has supported public and priv<strong>at</strong>e sector<br />
companies and project owners for more than 80 years in protecting, strengthening<br />
and making profitable their innov<strong>at</strong>ions (p<strong>at</strong>ents, brand names, designs and models).<br />
10 partners head up a team of 200 people whose skills are put into practice in all the<br />
str<strong>at</strong>egic aspects of industrial property.<br />
Regimbeau’s expertise (Paris and its 5 regional offices in Lyon, Rennes, Grenoble,<br />
Montpellier and Munich) can provide an intern<strong>at</strong>ional str<strong>at</strong>egy, while maintaining a<br />
personalized rel<strong>at</strong>ionship of very high quality with its clients.<br />
CELLECTIS<br />
BIORESEARCH<br />
102 avenue Gaston Roussel<br />
93230 ROMAINVILLE - FRANCE<br />
Phone: +33 1 41 83 99 00<br />
Fax: +33 1 41 83 99 03<br />
Email: event@cellectis-bioresearch.com<br />
Web site: www.cellectis-bioresearch.com<br />
Contact: David LATTO<br />
Cellectis bioresearch specialize in cell line engineering for biotherapeutic production<br />
& development. Our technology can be used to modify the DNA sequence of<br />
customer cell lines with very high precision. We can engineer cell lines to contain a<br />
re-targetable gene expression cassette <strong>at</strong> a genomic protein production hot-spot in<br />
order to gre<strong>at</strong>ly reduce screening costs & time, gener<strong>at</strong>e stable & isogenic cell lines,<br />
achieve consistent protein expression levels & simplify regul<strong>at</strong>ion. We can also knockout<br />
genes to improve product quality, reduce purific<strong>at</strong>ion processes & increase cell<br />
half-life & productivity. For example, we are knocking-out the glutamine synthetase<br />
gene in Lonza’s CHOK1SV cell line to improve the selection process for cre<strong>at</strong>ing highly<br />
productive recombinant cell lines.<br />
33
CHELATEC<br />
1 rue Aronnax<br />
44821 SAINT-HERBLAIN Cedex - FRANCE<br />
Phone: +33 2 51 86 19 59<br />
Fax: +33 2 51 86 15 65<br />
Email: jfgestin@chel<strong>at</strong>ec.fr<br />
Web site: www.chel<strong>at</strong>ec.fr<br />
Contact: Jean-François GESTIN<br />
Chel<strong>at</strong>ec is an independent company providing customized service in the specific<br />
fields of radiolabeling and preclinical research.<br />
Our mission is to assist the pharmaceutical and biotechnology industry in the<br />
identific<strong>at</strong>ion and selection process of drug candid<strong>at</strong>es using the radioactive tracer.<br />
The broad expertise of our multidisciplinary team and the quality of our technical<br />
resources guarantee you optimum support for subcontracted projects. We offer a<br />
unique environment of labor<strong>at</strong>ories accredited in both the handling of radionuclides<br />
and animal experiment<strong>at</strong>ion conducted on rodents.<br />
CILOA<br />
cc107 - B<strong>at</strong>iment 24<br />
Universite Montpellier II - Place E. B<strong>at</strong>aillon<br />
34095 MONTPELLIER Cedex 05 - FRANCE<br />
Phone: +33 4 67 14 39 97<br />
Fax: +33 4 67 14 42 86<br />
Email: robert.mamoun@univ-montp2.fr<br />
Web site: www.ciloaweb.com<br />
Contact: Robert MAMOUN<br />
Ciloa is a start-up company with a proprietary technology th<strong>at</strong> provides fully n<strong>at</strong>ive<br />
membrane proteins on n<strong>at</strong>ural nanovesicles. Single and multi-transmembrane<br />
domain proteins sorted on these vesicles harbor all their n<strong>at</strong>ural post-transl<strong>at</strong>ional<br />
modific<strong>at</strong>ions. This revolutionary pl<strong>at</strong>form allows to produce custom membrane<br />
proteins out of cells for:<br />
1) drug screening<br />
2) innov<strong>at</strong>ive therapies<br />
3) gener<strong>at</strong>ion of new vaccines & monoclonal antibodies<br />
4) developing new kind of diagnostic tools.<br />
34
CLICDATA<br />
Place Francois Mitterrand<br />
1 Tour Crédit Lyonnais<br />
59777 EURALILLE - FRANCE<br />
Phone: +33 3 20 12 52 67<br />
Fax: +33 3 59 35 04 10<br />
Email: iain.wallace@clicd<strong>at</strong>a.com<br />
Web site: www.infinisworld.com<br />
Contact: Iain WALLACE<br />
ClicD<strong>at</strong>a presents Infinis, the Business Intelligence software next gener<strong>at</strong>ion, which<br />
builds a d<strong>at</strong>awarehouse autom<strong>at</strong>ically on the fly, allows you to cre<strong>at</strong>e amazing<br />
dashboards and reports in a few minutes. Oper<strong>at</strong>ional in less than 4 weeks, Infinis<br />
makes your Business Analysts and decision makers more productive and more<br />
confidents in the d<strong>at</strong>a. 2 priorities, rapidity (deployment and interface) and efficiency<br />
both for business and IT… all of it <strong>at</strong> a contained cost! Intrigued?<br />
www.infinisworld.com<br />
COLCOM<br />
Cap Alpha<br />
Avenue de l’Europe - Clapiers<br />
34940 MONTPELLIER Cedex 9 - FRANCE<br />
Phone: +33 6 24 34 42 94<br />
Fax: +33 4 67 63 10 46<br />
Email: info@colcom.eu<br />
Web site: www.colcom.eu<br />
Contact: Fabien GRANIER<br />
Nanotechnology based on “tree-like” polymers of Lysine with various possibilities of<br />
implement<strong>at</strong>ion for health, diagnostic, biom<strong>at</strong>erials and environmental applic<strong>at</strong>ions<br />
(production from g to kg). COLCOM has an exclusive know-how in chemistry and is<br />
mainly interested in collabor<strong>at</strong>ive research with industrial and academic partners.<br />
Fields of interest: antibodies production, biomarkers characteriz<strong>at</strong>ion, preclinical<br />
drug, transport of macromolecules across biological barriers, gene transfection, drug<br />
delivery, fluorescent molecule encapsul<strong>at</strong>ion, cell culture, biological traces detection,<br />
w<strong>at</strong>er filtr<strong>at</strong>ion, in vitro diagnostic.<br />
35
DBV TECHNOLOGIES<br />
Pépinière Paris Santé Cochin<br />
29 rue du Faubourg Saint Jacques<br />
75014 PARIS - FRANCE<br />
Phone: +33 1 55 42 78 78<br />
Fax: +33 1 43 26 10 83<br />
Email: phbenhamou@dbv-technologies.com<br />
Web site: www.dbv-technologies.com<br />
Contact: Pierre-Henri BENHAMOU<br />
dbv<br />
technologies<br />
DBV Technologies is the only company in the world whose products are designed<br />
to epicutaneously deliver an allergen - via a skin p<strong>at</strong>ch on intact skin - in order to<br />
diagnose and tre<strong>at</strong> food allergies. DBV’s proprietary skin p<strong>at</strong>ch technology - VIASKIN ® -<br />
is a breakthrough epicutaneous p<strong>at</strong>ch th<strong>at</strong> can desensitize against peanuts, milk<br />
and other major food allergies with dram<strong>at</strong>ic reduction in anaphylaxis risk. DBV is<br />
currently involved in 2 clinical trials for the Peanut Specific Immunotherapy: a Phase<br />
Ib in the US and a pilote Phase II in France…<br />
DOMAIN THERAPEUTICS<br />
Bioparc<br />
Boulevard Sébastien Brant<br />
67400 ILLKIRCH - FRANCE<br />
Phone: +33 3 90 40 61 50<br />
Fax: +33 3 90 40 61 55<br />
Email: contact@domaintherapeutics.com<br />
Web site: www.domaintherapeutics.com<br />
Contact: Pascal NEUVILLE<br />
Domain Therapeutics is a biopharmaceutical company loc<strong>at</strong>ed in Strasbourg, France,<br />
dedic<strong>at</strong>ed to the discovery and early development of small molecules targeting<br />
G-coupled Protein Receptors (GPCRs).<br />
Domain Therapeutics is using its innov<strong>at</strong>ive and proprietary technology pl<strong>at</strong>form<br />
DTect- All to address difficult GPCRs such as orphan and peptidic GPCRs for leading<br />
indic<strong>at</strong>ions such as Parkinson’s disease, schizophrenia, Alzheimer’s disease and<br />
diabetes.<br />
36
ERYTECH PHARMA<br />
60 avenue Rockefeller<br />
B<strong>at</strong>iment Adenine<br />
69008 LYON - FRANCE<br />
Phone: +33 4 78 74 44 38<br />
Fax: +33 4 78 78 93 00<br />
Email: contact@erytech.com<br />
Web site: www.erytech.com<br />
Contact: Pierre Olivier GOINEAU<br />
ERYtech Pharma (Lyon, Philadelphia) is a specialty pharma company developing<br />
innov<strong>at</strong>ive therapeutic solutions based on its proprietary technology and expertise<br />
in the physiological properties of erythrocytes. The company addresses serious<br />
p<strong>at</strong>hologies, orphan indic<strong>at</strong>ions or sub-popul<strong>at</strong>ions of p<strong>at</strong>ients, particularly in the<br />
fields of hem<strong>at</strong>ology, cancer and metabolic diseases.<br />
ERYtech Pharma US Office: 3711 Market Street, 19104 Philadelphia PA – USA.<br />
EUROFINS OPTIMED<br />
1 rue des Essarts<br />
38610 GIERES - FRANCE<br />
Phone: +33 4 38 37 27 40<br />
Fax: +33 4 38 37 27 41<br />
Email: marie.gilbert-collet@optimed.fr<br />
Web site: www.optimed.fr<br />
Contact: Marie GILBERT-COLLET<br />
<strong>French</strong> company founded in 1990, EUROFINS OPTIMED provides services for Early<br />
Drug Development (First into Human and First into P<strong>at</strong>ient studies, PK/PD studies,<br />
Proof of concept, etc.). EUROFINS OPTIMED has its own facilities on 2 sites with a<br />
full capacity of 100 beds including a hospital based unit. Thanks to its position within<br />
the Lyon Sud Hospital, Eurofins Optimed has access to various type of p<strong>at</strong>ients and a<br />
large network of experts. In addition to its services in pharmacology, Eurofins Optimed<br />
offers all services needed to achieve your study: regul<strong>at</strong>ory services, medical writing,<br />
monitoring, d<strong>at</strong>a management and st<strong>at</strong>istics.<br />
37
EVEON<br />
345 rue Lavoisier<br />
Inovallée<br />
38330 MONTBONNOT SAINT MARTIN<br />
FRANCE<br />
Phone: +33 4 76 44 84 17<br />
Email: mco@eveon.eu<br />
Web site: www.eveon.eu/en/index.html<br />
Contact: Muriel COMBEAU<br />
Eveon presents the first completely autom<strong>at</strong>ic and programmable medical injection<br />
device, fully safe, for SQ, ID and IM administr<strong>at</strong>ion of drugs of viscosities from 1 to<br />
100cp.<br />
The product is declined in a pl<strong>at</strong>form of devices th<strong>at</strong> could be mono-dose or multidoses,<br />
single-use or reusable.<br />
These devices also address other high-value applic<strong>at</strong>ions such as autom<strong>at</strong>ic LYO<br />
reconstitution or/and autom<strong>at</strong>ic mixing or/and dual injection.<br />
FLAMEL TECHNOLOGIES<br />
33 avenue du Dr Georges Levy<br />
69693 VENISSIEUX - FRANCE<br />
Phone: +33 4 7278 34 34<br />
Fax: +33 4 72 78 34 35<br />
Email: licencing@flamel.com<br />
Web site: www.flamel.com<br />
Contact: Grégoire FRANOUX<br />
FLAMEL Technologies (Nasdaq : FLML) is a world leader in delivery systems for small<br />
and large molecule drugs. The company, headquartered in Lyon, France, uses two<br />
innov<strong>at</strong>ive technology pl<strong>at</strong>forms, Micropumps ® and Medusa ® , to develop better and<br />
safer drugs tackling unmet medical needs.<br />
Flamel has 270 employees (70 PhDs) and ongoing RD collabor<strong>at</strong>ions and license<br />
agreements with many of the leading pharmaceutical and biotechnology companies<br />
(including GSK, Merck-Serono, Baxter and Pfizer).<br />
38
GELARC<br />
(Groupe d’ etude des L ymphomes de L’AduLte-r echer che cLinique/ AduLt<br />
Lymphom A study Group- cLinic AL r eseAr ch)<br />
Centre Hospitalier Lyon-Sud<br />
Secteur Sainte Eugénie - Pavillon 6D<br />
165 chemin du Grand Revoyet<br />
69495 PIERRE-BENITE Cedex - FRANCE<br />
Phone: +33 4 72 66 93 33<br />
Fax: +33 4 72 66 38 67<br />
Email: pascal.deschaseaux@gelarc.org<br />
Web site: www.gelarc.org<br />
Contact: Pascal DESCHASEAUX<br />
GELARC is a leading non-profit academic organiz<strong>at</strong>ion devoted to clinical research in<br />
the exclusive field of lymphoma. Founded in 2000, it is the daughter organiz<strong>at</strong>ion of the<br />
world renowned lymphoma cooper<strong>at</strong>ive group GELA (Groupe d’Etude des Lymphomes<br />
de l’Adulte/Adult Lymphoma Study Group). GELARC promotes and runs phase I to III<br />
clinical trials, for GELA, its academic partners and the pharma and biotech industries,<br />
<strong>at</strong> a n<strong>at</strong>ional or intern<strong>at</strong>ional level.<br />
GENOWAY<br />
181 avenue Jean Jaures<br />
Immeuble Ch<strong>at</strong>eaubriand<br />
69362 LYON - FRANCE<br />
Phone: +33 4 37 65 41 00<br />
Fax: +33 4 37 65 41 01<br />
Email: info@genoway.com<br />
Web site: www.genoway.com<br />
Contact: Dr. Kader THIAM<br />
genOway is dedic<strong>at</strong>ed to the development of tailor-made transgenic r<strong>at</strong> and mouse<br />
models for target valid<strong>at</strong>ion and drug development programs through innov<strong>at</strong>ive<br />
technologies (humaniz<strong>at</strong>ion, RNAi, inducible system) improving the security and<br />
relevancy of in vivo programs.<br />
Moreover, genOway offers ready-to-use transgenic r<strong>at</strong> and mouse models as tools<br />
to increase the predictability of in vivo preclinical studies in immunology, neurology,<br />
metabolic disorders and ADMET.<br />
39
GENTICEL<br />
Prologue Biotech - BP 28262<br />
Rue Pierre et Marie Curie<br />
31670 LABEGE - FRANCE<br />
Phone: +33 5 61 28 70 60<br />
Fax: +33 5 61 28 70 69<br />
Email: ebonfils@genticel.com<br />
Web site: www.genticel.com<br />
Contact: Elisabeth BONFILS<br />
GENTICEL S.A. is a bio-pharmaceutical company th<strong>at</strong> develops therapeutic vaccines<br />
based on a unique antigen delivery technology called the Adenyl<strong>at</strong>e Cyclase (CyaA).<br />
The str<strong>at</strong>egic goals of Genticel are (1) to ensure th<strong>at</strong> a vaccine solution can be offered<br />
to all HPV infected women in order to prevent cervical cancer and (2) to render<br />
available a further enhanced CyaA-based antigen delivery pl<strong>at</strong>form, called Vaxiclase,<br />
for applic<strong>at</strong>ions in cancer, chronic viral and bacterial infectious diseases. Genticel,<br />
named BT Pharma until March 9, 2010, was formed in 2001 as a spin out from the<br />
Institut Pasteur in Paris and is currently headquartered in Labége (Toulouse), France.<br />
The company employs 29 people.<br />
HARMONIC PHARMA<br />
Espace Transfert<br />
615 rue du Jardin Botanique<br />
54600 VILLERS LES NANCY - FRANCE<br />
Phone: +33 3 54 95 86 04<br />
Email: souchet@harmonicpharma.com<br />
gegout@harmonicpharma.com<br />
Web site: www.harmonicpharma.com<br />
HARMONIC PHARMA’s core business is directed towards repurposing clinical or<br />
approved drugs in new therapeutic areas. The company offers an innov<strong>at</strong>ive Harmonic<br />
Valid<strong>at</strong>ion © solution which exploits spherical harmonic based represent<strong>at</strong>ions of<br />
molecular entities for drug repositioning, and which currently draws on experimental<br />
in vitro/ex vivo valid<strong>at</strong>ions in four main therapeutic areas: Alzheimer disease, Infectious<br />
diseases, Diabetes rel<strong>at</strong>ed diseases, and Cancer.<br />
40
HELIOS BIOSCIENCES<br />
8 rue du Général Sarrail<br />
94010 CRÉTEIL Cedex - FRANCE<br />
Email: info@heliosbiosciences.com<br />
Web site: www.heliosbiosciences.com<br />
Contact:<br />
Dr. Jean Baptiste DUMAS MILNE EDWARDS<br />
In HELIOS BIOSCIENCES WE are convinced th<strong>at</strong> signalling p<strong>at</strong>hways are of<br />
outstanding importance to understand and cure diseases. Thus, we have developed<br />
an integr<strong>at</strong>ed system biology pl<strong>at</strong>form dedic<strong>at</strong>ed to the building of dynamic models of<br />
cell signalling. We use transcriptomic and/or proteomic and/or metabolic d<strong>at</strong>a. These<br />
dynamic models are used to select therapeutic targets and/or biomarkers. Our models<br />
can be used also to search for multi-targets.The technology th<strong>at</strong> we have designed<br />
has been used to develop models of immunostimul<strong>at</strong>ion of T lymphocytes, dendritic<br />
cells and also to build models of neurodegener<strong>at</strong>ive diseases. Using our models of<br />
immunostimul<strong>at</strong>ion we have selected and in vitro valid<strong>at</strong>ed Immunosuppressive drug<br />
targets which belong to a new p<strong>at</strong>hway.<br />
We offer an access to our dynamic modelling technology. Various option starting from<br />
the building of a dedic<strong>at</strong>ed model to the internalis<strong>at</strong>ion of the technology are proposed.<br />
We also look for partners to develop our new targets.<br />
HEMARINA<br />
Aéropôle Centre<br />
29600 MORLAIX - FRANCE<br />
Phone: +33 2 98 88 88 23<br />
Fax: +33 2 98 88 38 94<br />
Email: info@hemarina.com<br />
Web site: www.hemarina.com<br />
Contact: Jacques CHASSERIAU<br />
Hemarina is a biotechnology company developing a new gener<strong>at</strong>ion of universal<br />
oxygen carrier for therapeutical and industrial applic<strong>at</strong>ions.<br />
41
HTL BIOTECHNOLOGY<br />
zI de L’Aumaillerie<br />
35133 JAVENE - FRANCE<br />
Phone: +33 2 99 99 37 37<br />
Email: contact@htl-bio.com<br />
Web site: www.htl-bio.com<br />
Contact: Todd KENWORTH<br />
HTL s.a.s. was cre<strong>at</strong>ed in 1992 and is specialized in the manufacture, purific<strong>at</strong>ion<br />
and research and development of Sodium Hyaluron<strong>at</strong>e (HA). It’s production is by<br />
biosynthesis using a n<strong>at</strong>ural, non OGM, bacterial strain (Mw from 1000 Dalton to<br />
4 million Dalton. HTL’s production facility is cGMP, holds Certific<strong>at</strong>es of Suitability with<br />
the European Pharmacopoeia for low and high Mw Sodium Hyaluron<strong>at</strong>e, is ISO 9001<br />
(2000) and has a Master File (MAF) filed with the FDA (US),the TGA (Australia) and<br />
the Ministry of Health in South Korea.<br />
ICDD<br />
100 route des houillères - BP 2<br />
13590 MEYREUIL - FRANCE<br />
Phone: +33 4 42 61 28 28<br />
Fax: +33 4 42 61 28 29<br />
Email: ncompagnone@icdd-sas.com<br />
Web site: www.icdd-sas.com<br />
Contact: N<strong>at</strong>halie COMPAGNONE<br />
ICDD is a french biotech dedic<strong>at</strong>ed to diagnostic biomarkers development in safety<br />
and personal medicine. Our safety biomarkers are based on 2 technologies, Mitosafe ®<br />
and Mitostream ® , and we offer services, partnership or technology transfert to<br />
our customer or partner. Compagnon biomarkers are gener<strong>at</strong>ed through the<br />
Promembrane ® technology on 2 unmeet medical needs: early diagnosis of Alzheimer<br />
<strong>at</strong> the MCI stage, and muscles adverses events in AIDS p<strong>at</strong>ients.<br />
42
IMABIOTECH<br />
B<strong>at</strong>iment SN3 Cite Scientifique<br />
59655 VILLENEUVE D’ASCQ - FRANCE<br />
Phone: +33 6 32 94 03 51<br />
Fax: +33 3 20 43 40 54<br />
Email: stauber.jon<strong>at</strong>han@imabiotech.com<br />
Web site: www.imabiotech.com<br />
Contact: Jon<strong>at</strong>han STAUBER<br />
ImaBiotech offers services and products with an innov<strong>at</strong>ive technology of mass<br />
spectrometry imaging.<br />
ImaBiotech is a contract research organiz<strong>at</strong>ion (CRO) which provides Mass<br />
Spectrometry Imaging services for preclinical research (ADME and pharmacokinetics<br />
studies). With innov<strong>at</strong>ions and improvement of this technology, ImaBiotech also<br />
develops a new tool for immunodiagnostics.<br />
IMMUNID TECHNOLOGIES<br />
17 rue des Martyrs<br />
38054 GRENOBLE Cedex 09 - FRANCE<br />
Phone: +33 4 38 78 57 70<br />
Fax: +33 4 38 78 58 37<br />
Email: services@immunid.com<br />
Web site: www.immunid.com<br />
Contact: Isabelle TANNEAU<br />
ImmunID is a molecular diagnostics company th<strong>at</strong> uses the immune repertoire as a<br />
dynamic biomarker. Our team is dedic<strong>at</strong>ed to bringing solutions for the assessment<br />
of the efficacy and safety of immunomodul<strong>at</strong>ors during clinical trials and for p<strong>at</strong>ient<br />
str<strong>at</strong>ific<strong>at</strong>ion, in the areas of oncology and infectious diseases. ImmunID recently<br />
introduced the innov<strong>at</strong>ive concept of Divpenia ® (www.divpenia.com), a clinical st<strong>at</strong>e<br />
of reduced T & B lymphocytes immune diversity th<strong>at</strong> correl<strong>at</strong>es with a higher risk<br />
of infection and mortality. Divpenia ® can be used as a biomarker for early diagnosis,<br />
prognosis, response to tre<strong>at</strong>ment monitoring and p<strong>at</strong>ient str<strong>at</strong>ific<strong>at</strong>ion.<br />
43
IN-CELL-ART<br />
1 place Alexis Ricordeau<br />
44093 NANTES - FRANCE<br />
Phone: +33 2 40 71 67 17<br />
Email: info@incellart.com<br />
Web site: www.incellart.com<br />
IN CELL ART is a french biopharmaceutical company specializing in preclinical and<br />
pharmaceutical development of nanocarriers for macromolecular drugs. Its founder<br />
and research team, which includes a Nobel Prize Laure<strong>at</strong>e, have designed new classes<br />
of vectors th<strong>at</strong> are organized on a nanometric scale, which enables them to cross the<br />
cell barrier efficiently and safely. Products:<br />
• antibody production by genetic immuniz<strong>at</strong>ion. IN CELL ART technologies allows<br />
rapid and low cost production of antibodies with better specificity and affinity<br />
• DNA vaccine and siRNA therapeutics.<br />
INDICIA BIOTECHNOLOGY<br />
33 avenue de la Californie<br />
69600 OULLINS - FRANCE<br />
Phone: +33 4 72 39 14 92<br />
Fax: +33 4 72 39 16 01<br />
Email: infos@indicia.fr<br />
Web site: www.indicia.fr<br />
Contact: Stéphane LEGASTELOIS<br />
Indicia Biotechnology, specialist in immunotechnology and biochemistry, provides<br />
R&D and Manufacturing contracts to the biopharmaceutical and in vitro diagnostic<br />
industries to support their research, development of bioanalytical methods and<br />
safe production (under ISO 9001:2008, ISO13485, QSR and GMP intern<strong>at</strong>ional quality<br />
standards).<br />
We offer tailor-made solutions to measure biological targets (companion diag tests,<br />
methods to evalu<strong>at</strong>e immunogenicity, assays for biomarkers, immunomonitoring, QC<br />
methods…). Our technical services include immunoassays development and particles<br />
technologies (ELISA, Multiplex assays, l<strong>at</strong>eral flow, Singulex technology, a ntibodies<br />
development…).<br />
44
INGEN BIOSCIENCES<br />
17 avenue du Parc<br />
91380 CHILLY-MAzARIN - FRANCE<br />
Phone: +33 1 69 79 64 80<br />
Fax: +33 1 69 79 05 35<br />
Email: kadjoua@ingenbiosciences.com<br />
Web site: www.ingenbiosciences.com<br />
Contact: Kisy ADJOUA<br />
The InGen BioSciences Group is a <strong>French</strong> integr<strong>at</strong>ed IVD company th<strong>at</strong> develops and<br />
markets innov<strong>at</strong>ive diagnostic kits for clinical use, especially in the areas of infectious<br />
diseases and immunology.<br />
Leveraging its strong expertise in immunodiagnostics, the R&D develops IVD tests<br />
from research step to product industrializ<strong>at</strong>ion including regul<strong>at</strong>ory affairs. In parallel,<br />
the commercial organiz<strong>at</strong>ion pursues customer s<strong>at</strong>isfaction by offering high value<br />
reagents combined with autom<strong>at</strong>ion. Based in Paris area, the InGen BioSciences<br />
Group is growing profitably with sales reaching EUR 21M in 2010.<br />
INNOBIOCHIPS<br />
1 rue du Professeur Calmette<br />
59000 LILLE - FRANCE<br />
Phone: +33 3 20 87 12 98<br />
Email: contact@innobiochips.fr<br />
Web site: www.innobiochips.fr<br />
Contact: Vianney SOUPLET<br />
Innobiochips helps researchers leverage novel microanalytical technologies and<br />
acceler<strong>at</strong>e their discovery projects.<br />
With tailor-made solutions based on indepth knowledge of biomolecular chemistry<br />
and bioassays, Innobiochips helps the pharmaceutical, agrifood, cosmetics and<br />
environment industries provide new analytical tools and achieve superior performance<br />
levels (epitope mapping, multiplex serology, multi-proteins quantific<strong>at</strong>ion, biomarkers<br />
discovery…).<br />
45
INSTITUT MERIEUX<br />
17 rue Bourgel<strong>at</strong><br />
69002 LYON - FRANCE<br />
Phone: +33 4 78 87 72<br />
Email:<br />
philippe.cleuzi<strong>at</strong>@institut-merieux.com<br />
Web site: www.institut-merieux.com<br />
Contact: Philippe CLEUzIAT<br />
Institut Mérieux is committing its experience in industrial biology to serve medicine<br />
and public health across the globe. To fight against infectious diseases and cancers, it<br />
imagines and develops new approaches in the fields of diagnostics, immunotherapy,<br />
food safety and nutrition. Its three bio-industrial companies: bioMérieux, Transgene<br />
and Mérieux NutriSciences, working closely with its entities devoted to innov<strong>at</strong>ion,<br />
such as ABL Inc and Mérieux Développement, have enabled major advances in<br />
medicine and public health. Throughout the world, it aims to make these solutions<br />
accessible to the gre<strong>at</strong>est number of people.<br />
IRIS PHARMA<br />
Allée Hector Pintus<br />
06610 LA GAUDE - FRANCE<br />
Phone: +33 4 93 59 49 59<br />
Fax: +33 4 93 59 49 50<br />
Email: info@iris-pharma.com<br />
Web site: www.iris-pharma.com<br />
Contact: Pierre-Paul ELENA<br />
Iris Pharma is an independent <strong>French</strong> CRO th<strong>at</strong> specializes in preclinical and clinical<br />
research in the field of ophthalmology. Founded in 1989 by Dr Pierre-Paul Elena, Iris<br />
Pharma offers its services and expertise in the development of ophthalmic drugs and<br />
ocular medical devices to the pharmaceutical industry, biotechnology companies, and<br />
research institutes around the world.<br />
The company has five main areas of activity: preclinical studies and services,<br />
clinical trials (Phase I to IV and medico-marketing surveys), bioanalysis, preclinical<br />
formul<strong>at</strong>ion and str<strong>at</strong>egic consulting.<br />
46
KAYENTIS<br />
4 route de la Noue<br />
91190 GIF-SUR-YVETTE - FRANCE<br />
Phone: +33 1 69 18 25 40<br />
Fax: +33 1 64 46 79 06<br />
Email: agenovese@kayentis.com<br />
Web site: www.kayentis.com<br />
Contact: Anthony GENOVESE<br />
KAYENTIS is the leading vendor and oper<strong>at</strong>or of solutions th<strong>at</strong> transmit handwritten<br />
text from paper to digital media for the healthcare industry. Based on KAYENTIS’<br />
Digital Pen and Paper pl<strong>at</strong>form, these solutions bring together the best the physical<br />
and digital worlds have to offer: the easiest collection method (paper and pen) offering<br />
the highest d<strong>at</strong>a quality combined with all the advantages of electronic management<br />
(real-time access to d<strong>at</strong>a, accur<strong>at</strong>e timestamps, audit trail fe<strong>at</strong>ures, alerts, distribution<br />
of relevant inform<strong>at</strong>ion to the right persons).<br />
KAYENTIS’ solutions are used for over 50,000 p<strong>at</strong>ients in 50 countries.<br />
LABORATOIRE ICARE<br />
BIOPOLE Clermont-Limagne<br />
63360 SAINT-BEAUzIRE - FRANCE<br />
Phone: +33 4 73 33 99 99<br />
Fax: +33 4 73 33 99 77<br />
Email: commercial@labor<strong>at</strong>oireicare.com<br />
Web site: www.labor<strong>at</strong>oire-icare.com<br />
Contact: Christian POINSOT<br />
Pharmaceutical establishment, certified ISO 9001, accredited by the COFRAC<br />
and strictly respecting the GMP and the FDA requirements, ICARE is a labor<strong>at</strong>ory<br />
specialized in the control of contamin<strong>at</strong>ion.<br />
The strength of ICARE, which technical and human resources enable him to work <strong>at</strong><br />
the intern<strong>at</strong>ional level, lies in its capacity to upgrade its services in accordance with<br />
the regul<strong>at</strong>ions and norm<strong>at</strong>ive changes in pharmaceutical, medical devices, veterinary,<br />
cosmetics and clinics fields.<br />
47
LFB<br />
3 avenue des tropiques<br />
zA de Courtaboeuf<br />
91940 LES ULIS - FRANCE<br />
Phone: +33 1 68 82 88 69<br />
Fax: +33 1 69 82 70 70<br />
Email: soubiesg@lfb.fr<br />
Web site: www.lfb.fr<br />
Contact: Gail SOUBIES<br />
LFB Group is a biopharmaceutical group th<strong>at</strong> develops, manufactures and markets<br />
medicinal products for the tre<strong>at</strong>ment of serious and often rare diseases in several<br />
major therapeutic areas: immunology, intensive care and hemostasis. LFB Group<br />
is the leading manufacturer of plasma-derived medicinal products in France and<br />
the 6th player worldwide. It is also among the leading European companies for<br />
the development of monoclonal antibodies and new-gener<strong>at</strong>ion proteins based on<br />
biotechnologies. In 2010, LFB’s turnover reached €411.6 million; €86.5 million were<br />
dedic<strong>at</strong>ed to the group’s R&D activities. Christian Béchon is president and CEO of the<br />
LFB Group (1835 employees). For more inform<strong>at</strong>ion about LFB: http://www.lfb.fr/<br />
MAGNISENSE<br />
27 chemin des Peupliers - BP 62<br />
69572 DARDILLY Cedex - FRANCE<br />
Phone: +33 1 45 62 82 64<br />
Email: info@magnisense.com<br />
Web site: www.magnisense.com<br />
Contact: Hay<strong>at</strong> EL YOUSFI<br />
Magnisense develops and markets magnetic bioassays. These next-gener<strong>at</strong>ion assays<br />
improve rapid diagnostic performance for human and animal diagnostics, food safety<br />
and environmental protection testing. They are based on magnetic bead markers,<br />
which can be used to achieve the accuracy of labor<strong>at</strong>ory testing with the ease of use<br />
of rapid test methods. Magnisense technology provides true quantific<strong>at</strong>ion of one or<br />
more biological targets, even in large volume samples. The magnetic signal is free of<br />
interference from environmental factors, permitting a more sensitive and reproducible<br />
detection than possible with traditional markers.<br />
48
MEDINCELL<br />
Cap Alpha<br />
Avenue de l’Europe<br />
34830 MONTPELLIER Cedex 9 - FRANCE<br />
Phone: +33 9 50 51 81 61<br />
Fax: +33 4 67 02 13 67<br />
Email: sebastien.enault@medincell.com<br />
Web site: www.medincell.com<br />
Contact: Sébastien ENAULT<br />
Medincell S.A. is a leading biopharmaceutical company loc<strong>at</strong>ed in France and USA<br />
th<strong>at</strong> offers an innov<strong>at</strong>ive Drug Delivery Pl<strong>at</strong>form, enhancing the delivery of active<br />
agents, improving p<strong>at</strong>ient compliance and convenience thanks to advantageous<br />
pharmacokinetic profiles.<br />
MEDIT<br />
2 rue du Belvédère<br />
91120 PALAISEAU - FRANCE<br />
Phone: +33 1 60 14 87 43<br />
or +1 (858)342 6807 (San Diego office)<br />
Fax: +33 1 83 63 67 46<br />
Email: fdelfaud@medit.fr<br />
srichard@medit.fr<br />
Web site: www.medit.fr<br />
MEDIT-SA develops innov<strong>at</strong>ive software to mine <strong>at</strong> Chemo-Proteomic level all<br />
Biostructural and SAR d<strong>at</strong>a. Applic<strong>at</strong>ions include: 1) Allosteric site detection •<br />
2) Functional annot<strong>at</strong>ion • 3) Binding site characteriz<strong>at</strong>ion • 4) Target druggability •<br />
5) Off target identific<strong>at</strong>ion • 6) Drug repurposing • 7) Scaffold hopping • 8) Bioisosterism<br />
replacement • 9) Fragment binding prediction • 10) Fragment-based drug design •<br />
11) Protein-protein interactions. In April 2011, we release MEDL-Bioisostere to provide<br />
bioisosteric replacement from protein-fragment local 3D similarities detected into the<br />
Protein D<strong>at</strong>a Bank, and MEDP-SiteClassifier to explore all binding site similarities <strong>at</strong><br />
PDB scale.<br />
49
METABRAIN RESEARCH<br />
4 avenue François Mitterrand<br />
91380 CHILLY-MAzARIN - FRANCE<br />
Phone: +33 1 69 19 41 50<br />
Fax: +33 1 69 19 41 51<br />
Email: contact@metabrainresearch.com<br />
Web site: www.metabrainresearch.com<br />
Contact: Valérie AUTIER<br />
Metabrain Research is a drug discovery Partnering Research Organis<strong>at</strong>ion (PRO)<br />
expert in metabolic disorders.<br />
Metabrain Research has a sustainable business model of early stage drug discovery<br />
research, based on a mix of research alliances, early stage collabor<strong>at</strong>ions and contract<br />
research. Our objectives <strong>at</strong> BIO :<br />
1) propose research alliances on first-in-class programs<br />
2) contribute to drug discovery programs through contract research<br />
3) initi<strong>at</strong>e collabor<strong>at</strong>ions building on the connections between metabolic and CNS<br />
disorders to valid<strong>at</strong>e novel targets and discover new drugs.<br />
MILLEGEN<br />
Immeuble Biostep - B<strong>at</strong>. A<br />
Rue Pierre et Marie Curie<br />
31681 LABEGE - FRANCE<br />
Phone: +33 5 61 28 70 10<br />
Fax: +33 5 61 28 70 11<br />
Email: contact@millegen.com<br />
Web site: www.millegen.com<br />
Contacts: Anne DEFLISQUE<br />
Philippe MONDON<br />
Millegen is expert in discovery and genetic engineering of therapeutic antibodies.<br />
MilleGen’s antibody pl<strong>at</strong>form allows the gener<strong>at</strong>ion of fully human monoclonal<br />
antibodies and lead optimiz<strong>at</strong>ion using a powerful Directed Molecular Evolution<br />
technology. Our specificity is to have a proprietary library comprising several billion<br />
different fully human antibodies with an original diversity. Our efficiency was proven<br />
through several successful projects with industrial partners. MilleGen has built<br />
a pipeline of therapeutic antibodies. We are looking to associ<strong>at</strong>e human antibody<br />
candid<strong>at</strong>es to original targets to develop with you a targeted therapy.<br />
50
NETRIS PHARMA<br />
Centre Léon Bérard<br />
28 rue Laennec<br />
69008 LYON - FRANCE<br />
Phone: +33 4 78 78 29 53<br />
Fax: +33 4 78 78 28 04<br />
Email: pascalenony@netrispharma.com<br />
Web site: www.netrispharma.com<br />
Contact: Pascale NONY<br />
NETRIS Pharma is a biotech company pioneer in the characteriz<strong>at</strong>ion and development<br />
of drug candid<strong>at</strong>es targeting the Dependence Receptors p<strong>at</strong>hway for cancer therapy.<br />
The therapeutic approach is based on cellular mechanisms identified by a worldrenowned<br />
research group and has not yet been explored by pharmaceutical companies.<br />
NETRIS Pharma evalu<strong>at</strong>es and develops drug candid<strong>at</strong>es until the end of preclinical<br />
or phase I and proposes licensing and collabor<strong>at</strong>ive agreements. NETRIS Pharma has<br />
several high-value candid<strong>at</strong>es in its pipeline for therapy of lung and breast cancers as<br />
well as neuroblastoma among others.<br />
NEUROFIT<br />
Boulevard Sébastien Brant<br />
Bioparc - Parc d’Innov<strong>at</strong>ion<br />
67400 ILLKIRCH - FRANCE<br />
Phone: +33 3 88 65 16 06<br />
Fax: +33 3 88 65 16 22<br />
Email: neurofit@neurofit.com<br />
Web site: www.neurofit.com<br />
Contact: Dr. Emile ANDRIAMBELOSON<br />
NEUROFIT is a pre-clinical CRO (Contract Research Organiz<strong>at</strong>ion) based in France<br />
and offering comprehensive list of disease models and screening assays in the fields<br />
of psychi<strong>at</strong>ry, neurology, multiple sclerosis, diabetes, pain and oncology. Neurofit’s<br />
expertise encompasses animal (in-vivo) experiment<strong>at</strong>ions and primary cell culture<br />
assays. Neurofit works for major pharmaceutical and Biotech companies in Europe<br />
and USA.<br />
51
NICOX<br />
1681 route des Dolines<br />
Les Taissounières - HB4 - BP 313<br />
06906 SOPHIA ANTIPOLIS - FRANCE<br />
Phone: +33 4 97 24 53 00<br />
Fax: +33 4 97 24 53 99<br />
Email: nicox@nicox.com<br />
Web site: www.nicox.com<br />
Contact: Gavin SPENCER<br />
NicOx is a pharmaceutical company focused on the research, development and<br />
future commercializ<strong>at</strong>ion of drug candid<strong>at</strong>es. NicOx is applying its proprietary nitric<br />
oxide-don<strong>at</strong>ing R&D pl<strong>at</strong>form to develop an internal portfolio of New Molecular<br />
Entities (NMEs) for the potential tre<strong>at</strong>ment of inflamm<strong>at</strong>ory, cardio-metabolic and<br />
ophthalmological diseases.<br />
NicOx’s lead investig<strong>at</strong>ional compound is naproxcinod, an NME in development for the<br />
relief of the signs and symptoms of osteoarthritis. In addition to naproxcinod, NicOx’s<br />
pipeline includes several nitric oxide-don<strong>at</strong>ing NMEs, which are in development<br />
internally and with partners, including Merck (known as MSD outside the United<br />
St<strong>at</strong>es and Canada) and Bausch + Lomb, for the tre<strong>at</strong>ment of select cardiovascular<br />
indic<strong>at</strong>ions, eye diseases and derm<strong>at</strong>ological diseases.<br />
NOKAD<br />
4 rue Pierre Fontaine<br />
91000 EVRY - FRANCE<br />
Phone: +33 1 60 87 89 86<br />
Fax: +33 1 60 87 89 99<br />
Email: contact@nokad-pharma.com<br />
Web site: www.nokad.fr<br />
Contact: Amine M. ABINA<br />
NOKAD has developed a target valid<strong>at</strong>ion pl<strong>at</strong>form using both in vivo and ex vivo<br />
models allowing the discovery of new p<strong>at</strong>hways in hem<strong>at</strong>ology and cancer with the<br />
aim to develop new therapeutic str<strong>at</strong>egies and biomarkers. NOKAD is developing a<br />
biomarker blood test to str<strong>at</strong>ify an individual risk of developing thrombosis following<br />
Erythropoietin tre<strong>at</strong>ment and in hypoxia-stressed p<strong>at</strong>ients. Other projects under<br />
development include therapeutic vaccin<strong>at</strong>ion in cancer and development of new<br />
vaccine str<strong>at</strong>egies in infectious diseases.<br />
52
NOSOPHARM<br />
Site EERIE - Parc Georges Besse<br />
30035 NIMES Cedex 01 - FRANCE<br />
Phone: +33 9 65 15 10 93<br />
Fax: +33 4 86 55 63 42<br />
Email: p.villainguillot@nosopharm.com<br />
Web site: www.nosopharm.com<br />
Contact: Philippe VILLAIN-GUILLOT<br />
Nosopharm discovers and develops novel first-in-class antibiotics by the medicinal<br />
mining of a novel microbial bioresource. Nosopharm aims to out-license its novel<br />
antibiotics <strong>at</strong> the preclinical stage.<br />
NOVALIX<br />
Bioparc<br />
Boulevard Sébastien Brant<br />
67400 ILLKIRCH - FRANCE<br />
Phone: +33 3 68 33 02 00<br />
Fax: +33 3 68 33 02 01<br />
Email: info@novalix-pharma.com<br />
Web site: www.novalix.com<br />
Contact: Denis zEYER<br />
NovAliX is focusing on the development of enabling chemistry and biophysical<br />
technologies to support the pharmaceutical industry’s outsourcing needs from<br />
discovery to manufacturing. With proprietary unique SPR technology, X-ray protein<br />
crystallography, supramolecular mass spectrometry and chemistry NovAliX offers<br />
comprehensive integr<strong>at</strong>ed services for small molecule drug discovery. With advanced<br />
NMR technologies, NovAliX provides fine characteriz<strong>at</strong>ion of biologics, thorough<br />
analysis of APIs and polymorphism studies to support pharmaceutical development<br />
and manufacturing teams.<br />
53
ONCODESIGN<br />
20 rue Jean Mazen - BP 27627<br />
21076 DIJON - FRANCE<br />
Phone: +33 3 80 78 82 60<br />
Fax: +33 3 80 78 82 61<br />
Email: spomeon@oncodesign.com<br />
jewing@oncodesign.com<br />
Web site: www.oncodesign.com<br />
Contact: Jon<strong>at</strong>han EWING<br />
The recent acquisition of the Nanocyclix technology pl<strong>at</strong>form is a perfect complement<br />
to Oncodesign’s recognized expertise and capabilities in transl<strong>at</strong>ional oncology<br />
research. Oncodesign’s capabilities now extend to therapeutic drug and diagnostic<br />
discovery offerings through an integr<strong>at</strong>ed, stand-alone approach. Chi-Mice ® pl<strong>at</strong>form:<br />
humanized mouse models consisting of low passage, p<strong>at</strong>ient-derived tumorgrafts<br />
as well as mice reconstituted with human immune system. PharmImage ® : a multimodality<br />
pharmaco-imaging pl<strong>at</strong>form for rodents equipped with MRI, MRS, PET and<br />
SPECT. Conventional pharmacology studies in mice and r<strong>at</strong>s.<br />
ONCOMEDICS<br />
1 avenue d’Ester<br />
87069 LIMOGES - FRANCE<br />
Phone: +33 5 55 33 85 25<br />
Fax: +33 5 55 33 85 26<br />
Email: contact@oncomedics.com<br />
Web site: www.oncomedics.com<br />
Contact: Christophe LAUTRETTE<br />
Oncomedics collect human cancer tumor from p<strong>at</strong>ients to obtain cancer primary<br />
culture as models for cancer research: drug screening, biomarker valid<strong>at</strong>ion… Our<br />
models are defined and valid<strong>at</strong>ed to evalu<strong>at</strong>e experimental drug efficiency on a panel<br />
of tumoral cell from distinct p<strong>at</strong>ient. Moreover, specific marker can be searched<br />
on our ex vivo models. Correl<strong>at</strong>ion between new drug candid<strong>at</strong>e and companion<br />
biomarker can be addressed too. We sell chemically defined medium for tumor cells<br />
conserv<strong>at</strong>ion, prepar<strong>at</strong>ion, and primary culture.<br />
54
ONLY FOR CHILDREN<br />
PHARMACEUTICALS<br />
Institut Villemin<br />
10 avenue de Verdun<br />
75010 PARIS - FRANCE<br />
Phone: +33 1 57 27 86 87<br />
or +33 6 98 71 02 12<br />
Fax: +33 1 57 27 86 80<br />
Email: estelle.habert-ortoli@o4cp.com<br />
Web site: www.o4cp.com<br />
Contact: Estelle HABERT-ORTOLI<br />
Only for children pharmaceuticals ® (O4CP) is a <strong>French</strong> pharmaceutical company (SAS)<br />
founded in 2007 developing adapted medicines for children. The company addresses<br />
an important unmet medical need th<strong>at</strong> experts and regul<strong>at</strong>ory authorities have clearly<br />
identified: the need for adapted medicines for children. O4CP is active in Oncology,<br />
Immunology, Infectious Diseases and Neurology, and present in Europe (Paris, France)<br />
and United St<strong>at</strong>es. O4CP is developing a pipeline of 8 molecules.<br />
OROXCELL<br />
102 avenue Gaston Roussel<br />
Parc Biocitech<br />
93230 ROMAINVILLE - FRANCE<br />
Phone: +33 1 41 83 72 20<br />
Fax: +33 1 41 83 72 27<br />
Email: christophe.dini@oroxcell.com<br />
Web site: www.oroxcell.com<br />
Contact: Christophe DINI<br />
Oroxcell is pursuing drug research and development of NCEs in the indic<strong>at</strong>ion of Pain.<br />
Oroxcell is seeking a partner wishing to undertake the development and marketing of<br />
the safe and active NCEs.<br />
Besides, Oroxcell is a well-recognized CRO offering a unique one-stop-shopping<br />
pl<strong>at</strong>form to assess skin and oral absorption (ADME) and Toxicity profile form issued<br />
life sciences industry. Oroxcell is actively involved in setting up unique predictive<br />
altern<strong>at</strong>ive technologies to animal. Oroxcell is GLP compliant for both cosmetic and<br />
pharmaceutical activities.<br />
55
PHARMAXON<br />
Parc Scientifique de Luminy - Case 922<br />
Grand Luminy Technopôle<br />
13288 MARSEILLE Cedex 9 - FRANCE<br />
Phone: +33 4 86 94 85 10<br />
Fax: +33 4 86 94 85 11<br />
Email: norreel@pharmaxon.com<br />
Web site: www.pharmaxon.com<br />
Contact: Jean-Chrétien NORREEL<br />
Founded in 2004, Pharmaxon is a mid-stage venture biopharmaceutical company<br />
developing first-in-class neurological disease therapeutics. Pharmaxon’s novel<br />
approach is linked to the pharmacological manipul<strong>at</strong>ion of “cell mobility”, a process<br />
central to many high unmet medical need neurological conditions. The goal of<br />
Pharmaxon’s in 2010 is to complete the preclinical toxicity studies for its lead molecule<br />
PR-21 (a spinal cord injury therapeutic with a wide range of additional high-value<br />
indic<strong>at</strong>ions).<br />
OXELTIS<br />
Cap Gamma<br />
1682 rue de la Valsière - CS 27384<br />
34189 MONTPELLIER Cedex 4 - FRANCE<br />
Phone: +33 4 99 23 50 36<br />
Fax: +33 9 70 06 43 82<br />
Email: contact@oxeltis.com<br />
Web site: www.oxeltis.com<br />
Contact: Jean-Marc ALLAIRE<br />
Oxeltis is a medicinal chemistry oriented service company for managing and executing<br />
projects involving medicinal and fine organic chemistry in the fields of pharmaceutical,<br />
diagnostic and academic research. Oxeltis has expertise in the fields of organic<br />
chemistry represented by nucleosides and nucleotides, heterocycles, macrocycles,<br />
Phosphorus and Flurorine Chemistry. Since February 2011, Oxeltis has put in place<br />
a routine nucleoside triphosph<strong>at</strong>e custom synthesis capability and has focused<br />
its knowhow in fields of applic<strong>at</strong>ion of medicinal chemistry in pharmaceutical drug<br />
discovery, and also in the field of diagnostic and research tools.<br />
56
PHENOPRO<br />
1 rue Laurent Fries<br />
67400 ILLKIRCH - FRANCE<br />
Phone: +33 3 88 65 57 36<br />
Fax: +33 3 88 65 56 07<br />
Email: francois.bocquel@phenopro.com<br />
Contact: François Bocquel<br />
PhenoPro is a spin off from IGBMC and the <strong>French</strong> Mouse Clinical Institute loc<strong>at</strong>ed in<br />
Strasbourg (France).<br />
PhenoPro is a pre-clinical Contract Research Organiz<strong>at</strong>ion dedic<strong>at</strong>ed to comprehensive<br />
mouse model phenotyping services with expertise in Cardiovascular, Metabolism and<br />
CNS & Behavior domains.<br />
The innov<strong>at</strong>ive approach of phenotyping with genetically-modified mice allows:<br />
• the process of discovering new drugs to be acceler<strong>at</strong>ed<br />
• shifts and delays to be avoided <strong>at</strong> l<strong>at</strong>er stages in the development plan<br />
• research costs to be optimised.<br />
POLYPLUS-<br />
TRANSFECTION<br />
Bioparc<br />
Boulevard Sebastien Brant<br />
67401 ILLKIRCH - FRANCE<br />
Phone: +33 3 90 40 61 80<br />
Fax: +33 3 90 40 61 81<br />
Email: info@polyplus-transfection.com<br />
Web site: www.polyplus-transfection.com<br />
Contact: Pascale BELGUISE<br />
Polyplus-transfection is a biotechnology company th<strong>at</strong> develops, markets and sells<br />
innov<strong>at</strong>ive solutions for in vivo, in vitro and ex vivo delivery of nucleic acids in research,<br />
bioproduction and therapeutics. Polyplus-transfection supplies its proprietary range<br />
of reagents for the transfection of genes, oligonucleotides and siRNA in vitro and in<br />
vivo through a worldwide distributor network. Polyplus-transfection reagents are<br />
involved into a growing number of clinical trials worldwide.<br />
57
PORSOLT<br />
9 bis rue Henri Martin<br />
92100 BOULOGNE-BILLANCOURT<br />
FRANCE<br />
Phone: +33 1 46 10 99 90<br />
Fax: +33 1 46 10 99 99<br />
Email: twolinsky@porsolt.com<br />
Web site: www.porsolt.com<br />
Contact: Dr. Toni WOLINSKY<br />
Priv<strong>at</strong>ely owned CRO, with over 25 years of experience, specialized in the preclinical<br />
evalu<strong>at</strong>ion of novel substances for their potential therapeutic activity (efficacy<br />
pharmacology) and adverse effects (safety pharmacology, including regul<strong>at</strong>ory<br />
GLP studies). We provide a wide range of in vivo p<strong>at</strong>hophysiological models and in<br />
vitro assays across a variety of disease areas covering CNS, pain & inflamm<strong>at</strong>ion,<br />
metabolic and cardiovascular diseases, and gastro-intestinal, renal/urogenital &<br />
respir<strong>at</strong>ory indic<strong>at</strong>ions, as well as evalu<strong>at</strong>ion of cardiovascular risk and drug abuse<br />
and dependence liability. We also offer in-life PK studies, including CSF sampling, in<br />
a number of species.<br />
POXEL<br />
200 avenue Jean Jaurès<br />
69007 LYON - FRANCE<br />
Phone: +33 4 37 37 20 10<br />
Fax: +33 4 37 70 88 15<br />
Email: contact@poxelpharma.com<br />
Web site: www.poxel.com<br />
Contact: Pascale MALGOUYRES<br />
Poxel is a biopharmaceutical company developing innov<strong>at</strong>ive first-in-class drugs<br />
with a primary focus on Type 2 diabetes. The company develops drug candid<strong>at</strong>es to<br />
clinical proof of concept before partnering with pharmaceutical companies. Poxel<br />
oper<strong>at</strong>es independently as a lean organiz<strong>at</strong>ion with strong in-house drug development<br />
expertise. Its pipeline consists in innov<strong>at</strong>ive projects with new mechanisms of action,<br />
with an activity on glucose metabolism, other cardiovascular risk factors and with an<br />
improved safety profile compared to currently available therapies.<br />
58
PRESTWICK CHEMICAL<br />
Boulevard Gonthier d’Andernach<br />
67400 STRASBOURG-Illkirch - FRANCE<br />
Phone: +33 3 69 20 16 00<br />
Fax: +33 3 69 20 16 17<br />
Email: infochem@prestwickchemical.fr<br />
Web site: www.prestwickchemical.com<br />
Contact: Paul BIKARD<br />
Prestwick Chemical is a drug discovery CRO th<strong>at</strong> successfully optimizes your hit<br />
into a clinical candid<strong>at</strong>e. With our premium partners, we offer fully integr<strong>at</strong>ed drug<br />
research: Hit identific<strong>at</strong>ion using smart screening libraries, hit valid<strong>at</strong>ion, hit to lead<br />
expansion, lead optimiz<strong>at</strong>ion and profiling. Our in-house expertise relies on long<br />
term experience in medicinal chemistry, with unprecedented success: 6 compounds<br />
made by Prestwick are currently in clinical development, from Phase I to Phase III. In<br />
l<strong>at</strong>e 2010, one project (developed jointly with Domain Therapeutics) was successfully<br />
licensed to Merck Serono.<br />
PROVEPHARM<br />
45 rue Frédéric Joliot Curie<br />
BP 100 - Technopôle Château Gombert<br />
13013 Marseille - FRANCE<br />
Phone: +33 4 91 11 87 59<br />
Fax: +33 4 91 11 88 11<br />
Email:<br />
christian.neumann@provepharm.com<br />
Web site: www.provepharm.com<br />
Contact: Christian NEUMANN<br />
Thanks to a p<strong>at</strong>ented synthesis p<strong>at</strong>h and genuine scientific work, PROVEPHARM<br />
revamped methylene blue compound as PROVEBLUETM Active Pharmaceutical<br />
Ingredient compliant with all pharmaceutical standards and ICH guidelines, developed<br />
the drug Proveblue Solution for Injection and obtained a centralized marketing<br />
authoriz<strong>at</strong>ion <strong>at</strong> EMA. It is now seeking to introduce the drug in US and to license-out<br />
the use of ProveblueTM API to parties interested in setting up exclusive partnerships<br />
to develop other drugs in well-defined applic<strong>at</strong>ions.<br />
59
PX’THERAPEUTICS<br />
Min<strong>at</strong>ec BHT 52B<br />
7 parvis Louis Néel<br />
38040 GRENOBLE - FRANCE<br />
Phone: +33 4 38 02 36 50<br />
Fax: +33 4 76 96 10 38<br />
Email: marketing@px-therapeutics.com<br />
Web site: www.px-therapeutics.com<br />
Contact: Claire UNTEREINER<br />
PX’Therapeutics provides services in the field of recombinant protein and monoclonal<br />
antibody development, from early research stage up to clinical manufacturing.<br />
We propose custom programs including, according to our clients’ needs, protein<br />
engineering, murine mAb development, mAb humaniz<strong>at</strong>ion, feasibility studies,<br />
process development, analytical method development & qualific<strong>at</strong>ion, process scaleup<br />
and GMP manufacturing.<br />
Through our subsidiary Promise Advanced Proteomics, we propose an innov<strong>at</strong>ive<br />
method of protein quantific<strong>at</strong>ion by Mass spectrometry.<br />
QUINTEN<br />
11 rue Galvani<br />
75017 PARIS - FRANCE<br />
Phone: +33 6 08 43 82 81<br />
Email: a.templier@quinten-france.com<br />
Web site: www.quinten-healthcare.com<br />
Contact: Alexandre TEMPLIER<br />
Quinten ® is specialized in Knowledge Extraction from Medical D<strong>at</strong>abases. Quinten’s<br />
core professional service consists in helping Pharma & Biotech companies identify the<br />
specific conditions in which their drugs show the best efficacy and safety performances,<br />
to better target their Research & Development programs and improve their success<br />
r<strong>at</strong>es. Quinten ® methodology and technology have proven to gener<strong>at</strong>e significant<br />
return on investment for its clients in various contexts such as early chemical lead<br />
optimiz<strong>at</strong>ion, Phase III study design optimiz<strong>at</strong>ion, and epidemiology / safety d<strong>at</strong>abases<br />
explor<strong>at</strong>ion.<br />
60
RHENOVIA PHARMA<br />
20C rue de Chemnitz<br />
68200 MULHOUSE - FRANCE<br />
Phone: +33 3 89 32 11 80<br />
Fax: +33 3 89 55 51 45<br />
Email: serge.bischoff@rhenovia.com<br />
Web site: www.rhenovia.com<br />
Contact: Serge BISCHOFF<br />
Rhenovia is a leading biotech company in biosimul<strong>at</strong>ion with a unique service offering<br />
for biopharma companies to acceler<strong>at</strong>e, reduce the costs and improve the success<br />
r<strong>at</strong>e of their Drug Development for neurodegener<strong>at</strong>ive and psychi<strong>at</strong>ric diseases. It<br />
uses breakthrough technology of modeling the cellular and molecular cascades of<br />
neuronal transmission and simul<strong>at</strong>ing functional biochemical and electrophysiological<br />
measures for in silico testing of drug effects under p<strong>at</strong>hological conditions. It further<br />
develops a high-tech r<strong>at</strong>e controlled p<strong>at</strong>ch for drugs and combin<strong>at</strong>ions optimized by<br />
simul<strong>at</strong>ion.<br />
ROOWIN<br />
102 avenue Gaston Roussel<br />
93230 ROMAINVILLE - FRANCE<br />
Phone: +33 6 61 95 34 50<br />
Fax: +33 1 41 83 71 94<br />
Email: p<strong>at</strong>rice.rool@roowin.fr<br />
Web site: www.roowin.com<br />
Contact: Dr. P<strong>at</strong>rice ROOL<br />
Roowin is a Contract Research/Manufacturing Organiz<strong>at</strong>ion (CRO/CMO) offering a one<br />
stop shopping services from early discovery research phase up to licensing out API in<br />
Phase II. These services include: hit to lead, lead optimiz<strong>at</strong>ion, process development,<br />
custom synthesis, cGMP production of API, analysis services, analytical method<br />
development, analytical method valid<strong>at</strong>ion, stability studies.<br />
Roowin’s team is formed with highly qualified scientific chemists: about 40 people<br />
(50% PhDs) working in 2000 m 2 of R&D labor<strong>at</strong>ories, kilo-labor<strong>at</strong>ory and pilot plant,<br />
equipped with adapted and efficient equipments.<br />
61
SYNTHELIS<br />
B<strong>at</strong>iment Biopolis<br />
5 avenue du Grand Sablon<br />
38700 LA TRONCHE - FRANCE<br />
Phone: +33 4 76 54 95 37<br />
Fax: +33 4 76 54 95 36<br />
Email: bruno.tillier@synthelis.fr<br />
Web site: www.synthelis.fr<br />
Contact: Bruno TILLIER<br />
Synthelis SAS is a start-up company providing a solution to a well known challenge<br />
in terms of biotechnological production, namely the development, characteriz<strong>at</strong>ion<br />
and production of customized membrane proteins and associ<strong>at</strong>ed service offerings.<br />
The company is also working on its own R&D programs with a view to developing<br />
innov<strong>at</strong>ive therapeutic and vaccine approaches based on membrane protein carried<br />
into liposomes<br />
TB DRUG BOOST<br />
3 rue du Professeur Laguesse<br />
59000 LILLE - FRANCE<br />
Phone: +33 3 20 96 40 24<br />
Fax: +33 3 20 96 49 07<br />
Web site: www.deprezlab.fr<br />
Anti-infective drug discovery. We have developed a pl<strong>at</strong>form specialized in screening<br />
for bacterial repressor inhibitiors. Our first program has produced several series<br />
specific nanomolar, bioavailable inhibitors of EthR, a myco-bacterial repressor. In vivo,<br />
these compounds boost the activity of ethionamide, a key antibiotic used in TB. Our<br />
series has reached the level of regul<strong>at</strong>ory development. We are seeking a partnership<br />
for the development of these compounds th<strong>at</strong> have a clinical utility in the tre<strong>at</strong>ment of<br />
MDR strains of tuberculosis.<br />
62
TEXCELL<br />
Genavenir 5<br />
1 rue Pierre Fontaine<br />
91058 EVRY Cedex - FRANCE<br />
Phone: +33 1 60 91 33 10<br />
Fax: +33 1 64 93 33 24<br />
Email: ybarbier@texcell.fr<br />
Web site: www.texcell.fr<br />
Contact: Yves BARBIER<br />
Texcell is a world-renowned CSO company th<strong>at</strong> provides viral safety and immunology<br />
services in full compliance with GLP and GMP standards.<br />
Thanks to our in-depth experience of providing viral safety testing and virus valid<strong>at</strong>ion<br />
studies, we have provided support to a large number of products now licensed by<br />
the FDA, the EMEA and the MHW. Texcell is also your central lab for pre-clinical and<br />
clinical trials. We offer a dedic<strong>at</strong>ed technology pl<strong>at</strong>form in immunology. Based in<br />
France (Evry), we cre<strong>at</strong>ed in 2009 a subsidiary in USA (NY).<br />
TFCHEM<br />
Voie de l’Innov<strong>at</strong>ion - PharmaParc 2<br />
27100 VAL DE REUIL - FRANCE<br />
Phone: +33 2 32 09 01 16<br />
Fax: +33 2 32 25 07 64<br />
Email:<br />
geraldine.deliencourt@tfchemistry.com<br />
Web site: www.tfchemistry.com<br />
Contact: Géraldine<br />
DELIENCOURT-GODEFROY<br />
TFChem is a drug-discovery company, subsidiary of Sirona Biochem, which uses<br />
the fluorine <strong>at</strong>om properties to develop new glycomimetic compounds: GlycoMim ®<br />
technology.<br />
TFChem brings a unique solution to the drawbacks usually associ<strong>at</strong>ed with<br />
carbohydr<strong>at</strong>e-based drugs and unlocks the potential of sugar for the development<br />
of new, more potent and safer drugs. TFChem targets several major pharmaceutical<br />
domains but also cosmetics and biological ingredients for cells preserv<strong>at</strong>ion. TFChem<br />
is building partnerships and licensing activity with pharmaceutical and biotechnological<br />
companies.<br />
63
THERALPHA<br />
2229 route des Crêtes<br />
06560 VALBONNE SOPHIA ANTIPOLIS<br />
FRANCE<br />
Phone: +33 6 25 183 239<br />
Email: david@theralpha.com<br />
Web site: www.theralpha.com<br />
Contact: David DELLAMONICA<br />
Theralpha is a specialty pharmaceutical company focused on the development and<br />
commercializ<strong>at</strong>ion of innov<strong>at</strong>ive therapies for the tre<strong>at</strong>ment pain. Our lead product,<br />
THA903, is designed to address acute pain by sublingual administr<strong>at</strong>ion. We have<br />
three additional product candid<strong>at</strong>es in preclinical development. We are advancing<br />
next gener<strong>at</strong>ion pain drugs based on scientifically valid<strong>at</strong>ed Acid Sensing Ion Channel<br />
(ASIC) p<strong>at</strong>hways. Theralpha aims to develop its pipeline to address unmet medical<br />
need in pain, a significant economic burden. We currently have four product candid<strong>at</strong>es<br />
in development.<br />
TRANSGENE<br />
Boulevard Gonthier d’Andernach<br />
Parc d’Innov<strong>at</strong>ion - CS 80166<br />
67405 ILLKIRCH Cedex - FRANCE<br />
Phone: +33 3 88 27 91 00<br />
Fax: +33 3 88 27 91 11<br />
Email: communic<strong>at</strong>ion@transgene.fr<br />
Web site: www.transgene.fr<br />
Contact: Jean-Yves BONNEFOY<br />
Transgene is a fully integr<strong>at</strong>ed biopharmaceutical company th<strong>at</strong> designs and develops<br />
cutting-edge immunotherapeutic products to tre<strong>at</strong> cancers and chronic infectious<br />
deseases. Our expertise covers all stages of product development, from research to<br />
the manufacture of clinical b<strong>at</strong>ches, and the conducting of clinical trials.<br />
64
TROPHOS<br />
Parc Scientifique de Luminy - Case 931<br />
13288 MARSEILLE Cedex 9 - FRANCE<br />
Phone: +33 4 91 82 82 82<br />
Fax: +33 4 91 82 82 89<br />
Email: info@trophos.com<br />
Web site: www.trophos.com<br />
Contact: Damian MARRON<br />
Trophos is a l<strong>at</strong>e stage pharmaceutical company whose str<strong>at</strong>egy is to cre<strong>at</strong>e and realise value<br />
from its proprietary, innov<strong>at</strong>ive, cholesterol-oxime compound family of mitochondrial pore<br />
modul<strong>at</strong>ors by taking <strong>at</strong> least one program to clinical valid<strong>at</strong>ion for orphan/niche indic<strong>at</strong>ions<br />
in neurology and acute cardiology. Trophos lead product, olesoxime, is in an ongoing pivotal,<br />
phase 3 efficacy study in the orphan indic<strong>at</strong>ion of Amyotrophic L<strong>at</strong>eral Sclerosis (ALS) with<br />
results due fourth quarter of 2011. The study is substantially funded by a €6M EU grant<br />
(MitoTarget). The target market potential is $1Bn per annum. A second orphan indic<strong>at</strong>ion for<br />
olesoxime is SMA. A pivotal efficacy study, substantially funded by the AFM p<strong>at</strong>ient associ<strong>at</strong>ion,<br />
is ongoing with results due second half of 2013. Market potential is $200M per annum.<br />
TRO40303, Trophos’ cardiology product in the niche, acute, hospital indic<strong>at</strong>ion of cardiac IRI<br />
has successfully completed phase 1. A phase 2 POC trial will start in the second half of 2011<br />
with results due second half 2012. The study will be funded by a €6M EU grant (MitoCare).<br />
Market potential is around $500M per annum.<br />
Trophos has two str<strong>at</strong>egic deals with Actelion Ltd; an Acquisition Option Agreement and a<br />
Research Collabor<strong>at</strong>ion Agreement.<br />
VALYSCO<br />
4 place d’Ainay<br />
69002 LYON - FRANCE<br />
Phone: +33 4 72 41 09 02<br />
Fax: +33 4 72 41 08 93<br />
Email: francois.guillemin@valysco.com<br />
contact @valysco.com<br />
Web site: www.valysco.com<br />
VALYSCO is an “oper<strong>at</strong>ional consultancy organiz<strong>at</strong>ion” dedic<strong>at</strong>ed to the development<br />
of Life Sciences through the counselling of priv<strong>at</strong>e and public stake holders in human,<br />
animal, plant health and nutrition.<br />
In an intern<strong>at</strong>ional environment, VALYSCO contributes to a more efficient global &<br />
transversal development of your projects, from Research to Market , from prevention<br />
(nutrition, vaccines, diagnostics…) to tre<strong>at</strong>ment (pharmaceuticals, diagnostics…) and<br />
well being.<br />
65
VIVALIS<br />
6 rue Alain Bombard<br />
44821 SAINT HERBLAIN - FRANCE<br />
Phone: +33 2 28 07 37 10<br />
Fax: +33 2 28 07 37 11<br />
Email: info.vivalis@vivalis.com<br />
Web site: www.vivalis.com<br />
Contact: Frédéric LEGROS<br />
VIVALIS (NYSE- Euronext: VLS) is a biopharmaceutical company th<strong>at</strong> provides<br />
innov<strong>at</strong>ive cell-based solutions to the pharmaceutical industry for the manufacture of<br />
vaccines and proteins and for the discovery of drugs for the prevention and tre<strong>at</strong>ment<br />
of unmet medical needs using 3 pl<strong>at</strong>forms:<br />
1) The EB66 ® Cell line used for the production of viral vaccines and monoclonal<br />
antibodies with enhanced cytotoxic activity.<br />
2) HUMALEX ® pl<strong>at</strong>form used for the discovery fully human monoclonal antibodies<br />
from human B lymphocytes.<br />
3) 3D-Screen pl<strong>at</strong>form used for identifying original molecules th<strong>at</strong> alter the threedimensional<br />
structure of a target protein.<br />
X’PROCHEM<br />
Cité scientifique<br />
Bâtiment Delamare - 4 e étage<br />
59655 VILLENEUVE D’ASCQ - FRANCE<br />
Phone: +33 3 20 43 46 69<br />
Fax: +33 3 20 43 41 75<br />
Email: reda.mhidia@gmail.fr<br />
Contact: Reda MHIDIA<br />
Chemical synthesis of proteins is an essential part of biopharmaceuticals<br />
development. X’ProChem offers a full range of custom chemical synthesis of proteins<br />
and manufacturing services to the life science and biopharmaceutical industries.<br />
Whether you are developing peptide and proteins (up to 300AA) as drug therapies,<br />
probing disease mechanisms, our science and production capability can work for you.<br />
Outsourcing your activity to X’ProChem is an efficient, cost-effective way of ensuring<br />
oper<strong>at</strong>ional productivity for your new Biopharmaceutical development through the<br />
pipeline.<br />
66
ZOPHIS<br />
5 rue de la Baume<br />
75008 PARIS - FRANCE<br />
Phone: +33 6 73 69 12 73<br />
Email: f.miceli@zophis.com<br />
Contact: François MICELI<br />
Acquisition and in-licensing of preclinical stage baccine development projects.<br />
67
BIOTECHNOLOGY AND<br />
RELATED SPECIALITIES<br />
AUTOIMMUNE THERAPIES<br />
Assistance Publique<br />
Hôpitaux de Paris<br />
Eveon<br />
PX'Therapeutics<br />
Atlanpole Biotherapies FLAMEL Technologies TcL Pharma<br />
Cabinet Regimbeau<br />
Innobiochips<br />
ERYTech Pharma<br />
Lyonbiopole<br />
BIOTECHNOLOGY COMPANY<br />
acCInov DBV Technologies Nokad<br />
Affilogic Domain Therapeutics Novalix<br />
Alaxia ERYTech Pharma Oncodesign<br />
Alize Pharma Eveon Oncomedics<br />
Animascope FLAMEL Technologies Oroxcell<br />
ANS Biotech genOway Pharmaxon<br />
Ariana Pharmaceuticals Genticel PhenoPro<br />
Assistance Publique<br />
Hôpitaux de Paris<br />
Hemarina<br />
Polyplus-transfection<br />
Atlanpole Biotherapies HTL Biotechnology Poxel<br />
Auvergne Biocluster ICDD PX’Therapeutics<br />
BioFilm Control In-Cell-Art Rhenovia Pharma<br />
Bio-Modeling Systems InGen BioSciences Synthelis<br />
Biopôle Clermont-Limagne Innobiochips TcL Pharma<br />
Cabinet Regimbeau Institut Merieux Texcell<br />
Capbiotek LFB Theralpha<br />
Cellectis Bioresearch Lyonbiopole Transgène<br />
Chel<strong>at</strong>ec Magnisense Vivalis<br />
Ciloa Metabrain Research X'ProChem<br />
Colcom MilleGen Zophis<br />
CRITT Santé Bretagne<br />
Netris Pharma<br />
CELL BIOLOGY<br />
acCInov Cabinet Regimbeau ICDD<br />
Almetis Cancer-Bio-Santé Medicen Paris Region<br />
Animascope Capbiotek Oncomedics<br />
Assistance Publique<br />
Hôpitaux de Paris<br />
CRITT Santé Bretagne Oroxcell<br />
Atlanpole Biotherapies Domain Therapeutics Polyplus-transfection<br />
CYTOLOGY<br />
acCInov Cabinet Regimbeau CRITT Santé Bretagne<br />
Assistance Publique<br />
Hôpitaux de Paris<br />
Capbiotek<br />
Oncomedics<br />
DEVICES<br />
Assistance Publique<br />
Hôpitaux de Paris<br />
DBV Technologies Magnisense<br />
Cabinet Regimbeau Eveon Medicen Paris Region<br />
Cancer-Bio-Santé Innobiochips<br />
Only For Children<br />
Pharmaceuticals<br />
Capbiotek<br />
Institut Merieux<br />
Université de Lyon<br />
Lyon Science Transfert<br />
CRITT Santé Bretagne<br />
Lyonbiopole
BIOTECHNOLOGY AND<br />
RELATED SPECIALITIES<br />
DIAGNOSTICS<br />
Assistance Publique<br />
Hôpitaux de Paris<br />
CRITT Santé Bretagne Medicen Paris Region<br />
Atlanpole Biotherapies DBV Technologies Nokad<br />
BioFilm Control ICDD Oncodesign<br />
Biopôle Clermont-Limagne ImmunID Technologies Oncomedics<br />
BioSIMS Technologies InGen BioSciences PX'Therapeutics<br />
Cabinet Regimbeau Innobiochips Quinten<br />
Cancer-Bio-Santé Institut Merieux<br />
Université de Lyon<br />
Lyon Science Transfert<br />
Capbiotek<br />
Lyonbiopole<br />
Colcom<br />
Magnisense<br />
DRUG DELIVERY<br />
Animascope Capbiotek Imabiotech<br />
Assistance Publique<br />
Hôpitaux de Paris<br />
Colcom<br />
Lyonbiopole<br />
Atlanpole Biotherapies CRITT Santé Bretagne Medicen Paris Region<br />
BioFilm Control DBV Technologies Medincell<br />
Biopôle Clermont-Limagne Eveon Rhenovia Pharma<br />
Cabinet Regimbeau FLAMEL Technologies TFChem<br />
Cancer-Bio-Santé HTL Biotechnology<br />
Université de Lyon<br />
Lyon Science Transfert<br />
DRUG DISCOVERY<br />
Adocia CRITT Santé Bretagne Oncodesign<br />
Almetis<br />
Domain Therapeutics<br />
Only For Children<br />
Pharmaceuticals<br />
Animascope ERYTech Pharma Oroxcell<br />
ANS Biotech Harmonic Pharma Pharmaxon<br />
Assistance Publique<br />
Hôpitaux de Paris<br />
Imabiotech<br />
PhenoPro<br />
Atlanpole Biotherapies Lyonbiopole Prestwick Chemical<br />
Auvergne Biocluster Medicen Paris Region PX'Therapeutics<br />
Bio-Modeling Systems Medincell Quinten<br />
Biopôle Clermont-Limagne Medit Rhenovia Pharma<br />
BioSIMS Technologies Metabrain Research Roowin<br />
Cabinet Regimbeau MilleGen TB Drug Boost<br />
Cancer-Bio-Santé NicOx TcL Pharma<br />
Capbiotek<br />
Nosopharm<br />
Université de Lyon<br />
Lyon Science Transfert<br />
Colcom<br />
Novalix<br />
FOOD AND AGRICULTURE<br />
Animascope Biopôle Clermont-Limagne Capbiotek<br />
Bio-Modeling Systems Cabinet Regimbeau Institut Merieux<br />
GENE THERAPY<br />
acCInov Cabinet Regimbeau Institut Merieux<br />
Animascope Colcom Medicen Paris Region<br />
Assistance Publique<br />
Hôpitaux de Paris<br />
CRITT Santé Bretagne PhenoPro<br />
Atlanpole Biotherapies In-Cell-Art Polyplus-transfection
BIOTECHNOLOGY AND<br />
RELATED SPECIALITIES<br />
GENOMICS<br />
Assistance Publique<br />
CRITT Santé Bretagne<br />
Hôpitaux de Paris<br />
Cabinet Regimbeau<br />
Capbiotek<br />
PhenoPro<br />
Medicen Paris Region<br />
Oncomedics<br />
IMMUNOCHEMICALS<br />
acCInov Cabinet Regimbeau Lyonbiopole<br />
Animascope FLAMEL Technologies Zophis<br />
Assistance Publique - Hôpitaux de Paris<br />
Innobiochips<br />
INDUSTRIAL AND ENVIRONMENTAL<br />
Bio-Modeling Systems Cabinet Regimbeau Eveon<br />
Biopôle Clermont-Limagne<br />
Capbiotek<br />
MOLECULAR BIOLOGY<br />
Almetis Domain Therapeutics Lyonbiopole<br />
Assistance Publique<br />
Hôpitaux de Paris<br />
Eveon<br />
Medicen Paris Region<br />
Cabinet Regimbeau ImmunID Technologies PhenoPro<br />
Capbiotek In-Cell-Art Quinten<br />
CRITT Santé Bretagne<br />
Institut Merieux<br />
PHARMACEUTICAL COMPANY<br />
Alzprotect<br />
Cabinet Regimbeau<br />
Only For Children<br />
Pharmaceuticals<br />
ANS Biotech Eveon PhenoPro<br />
Auvergne Biocluster FLAMEL Technologies Provepharm<br />
BioFilm Control Medincell Quinten<br />
Bio-Modeling Systems NicOx Trophos<br />
Biopôle Clermont-Limagne<br />
Novalix<br />
PROTEOMICS<br />
acCInov Cancer-Bio-Santé Innobiochips<br />
Assistance Publique<br />
Hôpitaux de Paris<br />
Capbiotek<br />
Lyonbiopole<br />
Atlanpole Biotherapies CRITT Santé Bretagne MEDIT<br />
Bio-Modeling Systems ICDD Oncomedics<br />
BioSIMS Technologies Imabiotech PX'Therapeutics<br />
Cabinet Regimbeau<br />
InGen BioSciences<br />
THERAPEUTICS<br />
Alize Pharma Domain Therapeutics NicOx<br />
Almetis ERYTech Pharma Nokad<br />
Assistance Publique<br />
Hôpitaux de Paris<br />
Eveon<br />
Oncodesign<br />
Bio-Modeling Systems FLAMEL Technologies<br />
Only For Children<br />
Pharmaceuticals<br />
Biopôle Clermont-Limagne Harmonic Pharma Provepharm<br />
Cabinet Regimbeau Institut Merieux PX'Therapeutics<br />
Capbiotek<br />
Lyonbiopole<br />
Université de Lyon<br />
Lyon Science Transfert<br />
CRITT Santé Bretagne Medicen Paris Region Zophis<br />
DBV Technologies<br />
Metabrain Research
EQUIPMENT<br />
AND SUPPLIES<br />
CELL/TISSUE CULTURE<br />
acCInov Harmonic Pharma Polyplus-transfection<br />
Assistance Publique<br />
Hôpitaux de Paris<br />
ICDD<br />
Texcell<br />
Cabinet Regimbeau LFB Trophos<br />
Capbiotek<br />
Netris Pharma<br />
Colcom<br />
Oncomedics<br />
CHEMICALS AND REAGENTS<br />
Assistance Publique<br />
Hôpitaux de Paris<br />
Colcom<br />
Institut Merieux<br />
Cabinet Regimbeau Innobiochips Oxeltis<br />
CHROMATOGRAPHY<br />
acCInov Iris Pharma Trophos<br />
Cabinet Regimbeau<br />
Oxeltis<br />
Imabiotech<br />
Texcell<br />
KITS/ASSAYS/ANTIBODIES<br />
Assistance Publique<br />
Hôpitaux de Paris<br />
Cellectis Bioresearch Institut Merieux<br />
BioSIMS Technologies Colcom Magnisense<br />
Cabinet Regimbeau ICDD Netris Pharma<br />
Cancer-Bio-Santé InGen BioSciences Texcell<br />
Capbiotek<br />
Innobiochips<br />
LAB EQUIPMENT/SUPPLIER<br />
Cabinet Regimbeau InGen BioSciences Texcell<br />
Capbiotek<br />
Institut Merieux<br />
Imabiotech<br />
MEDIT<br />
Cabinet Regimbeau<br />
LIQUIDE HANDLING<br />
Eveon<br />
MEASUREMENT AND ANALITYCAL INSTRUMENTATION<br />
BioSIMS Technologies Imabiotech Oxeltis<br />
Cabinet Regimbeau<br />
Innobiochips<br />
Colcom<br />
Magnisense<br />
MICROSCOPY<br />
BioSIMS Technologies ICDD Oncomedics<br />
Cabinet Regimbeau Iris Pharma Texcell<br />
Capbiotek Netris Pharma Trophos<br />
acCInov<br />
Cabinet Regimbeau<br />
PROCESSING EQUIPMENT<br />
Capbiotek<br />
Harmonic Pharma<br />
Cabinet Regimbeau<br />
PUMPS<br />
Eveon
EQUIPMENT<br />
AND SUPPLIES<br />
SAMPLE PREPARATION<br />
Cabinet Regimbeau Imabiotech Iris Pharma<br />
Capbiotek Institut Merieux Oncomedics<br />
SCALES<br />
Cabinet Regimbeau<br />
SPECTROSCOPY<br />
BioSIMS Technologies Cabinet Regimbeau Imabiotech<br />
VACCUM TECHNOLOGY<br />
Cabinet Regimbeau<br />
SCIENTIFIC, RESEARCH<br />
AND CONTRACT SERVICES<br />
ACCREDIDATION AND CERTIFICATION SERVICES<br />
Atlanpole Biotherapies Eveon Oroxcell<br />
BIOPROCESSING AND CHEMICAL PRODUCTION<br />
acCInov Colcom X’ProChem<br />
Atlanpole Biotherapies<br />
Capbiotek<br />
Institut Merieux<br />
Synthelis<br />
CLINICAL AND REGULATORY SERVICES<br />
acCInov Avogadro Iris Pharma<br />
Am<strong>at</strong>si<br />
Biotrial<br />
Only For Children<br />
Pharmaceuticals<br />
Analgesia Partnership Capbiotek Texcell<br />
Assistance Publique - Hôpitaux de Paris<br />
Eveon<br />
Atlanpole Biotherapies<br />
ImmunID Technologies<br />
CONTRACT MANUFACTURING<br />
acCInov Cancer-Bio-Santé Roowin<br />
Am<strong>at</strong>si Colcom Vivalis<br />
Analgesia Partnership Eveon X'ProChem<br />
Atlanpole Biotherapies Oxeltis<br />
Avogadro<br />
PX’Therapeutics<br />
CONTRACT RESEARCH<br />
Aepodia Chel<strong>at</strong>ec Neurofit<br />
Am<strong>at</strong>si Ciloa Nosopharm<br />
Analgesia Partnership Colcom Novalix<br />
Animascope Eurofins Optimed Oncomedics<br />
ANS Biotech<br />
Eveon<br />
Only For Children<br />
Pharmaceuticals<br />
Atlanpole Biotherapies genOway Oroxcell<br />
Atlantic Bone Screen Harmonic Pharma Oxeltis<br />
Auvergne Biocluster ICDD PhenoPro<br />
Avogadro Imabiotech Porsolt<br />
Bio-Modeling Systems In-Cell-Art Prestwick Chemical<br />
BioSIMS Technologies InGen BioSciences Provepharm<br />
Biotrial Innobiochips Rhenovia Pharma<br />
Cabinet Regimbeau Iris Pharma Roowin<br />
Cancer-Bio-Santé<br />
MEDIT<br />
Capbiotek<br />
Metabrain Research
SCIENTIFIC, RESEARCH<br />
AND CONTRACT SERVICES<br />
LABORATORY, ANALITYCAL AND TESTING SERVICES<br />
acCInov Imabiotech Oncomedics<br />
Am<strong>at</strong>si ImmunID Technologies Provepharm<br />
Analgesia Partnership In-Cell-Art PX'Therapeutics<br />
Atlanpole Biotherapies Innobiochips Quinten<br />
Atlantic Bone Screen Iris Pharma Roowin<br />
Avogadro Labor<strong>at</strong>oire ICARE Texcell<br />
Cancer-Bio-Santé<br />
Capbiotek<br />
Neurofit<br />
Oncodesign<br />
RESEARCH ORGANIzATION/INSTITUTE<br />
Analgesia Partnership CRITT Santé Bretagne Provepharm<br />
Assistance Publique<br />
Hôpitaux de Paris<br />
Eveon<br />
Quinten<br />
Atlanpole Biotherapies GELARC Roowin<br />
Cancer-Bio-Santé Institut Merieux TB Drug Boost<br />
Canceropole CLARA Neurofit Trophos<br />
Capbiotek<br />
PhenoPro<br />
OTHER<br />
Science Park<br />
Heuristic Systems biology ;<br />
Heuristic Integr<strong>at</strong>ive Biology<br />
Genome engineering<br />
Business Intelligence Reporting<br />
and Analytics<br />
Vaccines<br />
Drug repositioning or repurposing<br />
Dynamic system biology<br />
IVD tests development<br />
Technology provider<br />
Software vendor, Bio-cheminform<strong>at</strong>ics,<br />
drug design, molecular modeling,<br />
biostructure<br />
Preclinical services<br />
R&D for genes<br />
and oligonucleotides delivery<br />
Consulting<br />
Biocitech<br />
Bio-Modeling Systems<br />
Cellectis Bioresearch<br />
ClicD<strong>at</strong>a<br />
Genticel<br />
Harmonic Pharma<br />
Helios Biosciences<br />
InGen BioSciences<br />
Kayentis<br />
MEDIT<br />
Neurofit<br />
Polyplus-transfection<br />
Valysco
NOTES<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
NOTES<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
The <strong>French</strong> particip<strong>at</strong>ion<br />
is organized by<br />
<strong>UBIFRANCE</strong><br />
The <strong>French</strong> Agency for Intern<strong>at</strong>ional<br />
Business Development<br />
Head Office in Paris<br />
77 boulevard Saint-Jacques<br />
75014 PARIS - FRANCE<br />
Contact: Malika HACHEMI<br />
Phone: +33 1 40 73 35 70<br />
Fax: +33 1 40 73 32 02<br />
Email: malika.hachemi@ubifrance.fr<br />
Web site: www.ubifrance.fr<br />
Contacts in USA<br />
San Francisco - Mr Benoit COLINOT<br />
88 Kearny Street - Suite 700<br />
CA 94108 SAN FRANCISCO<br />
Phone: +1 415 568 4566<br />
Email: benoit.colinot@ubifrance.fr<br />
Web: www.ubifrance.fr
Change language